Sponsors for CUKC 2015

We would like to extend a warm thank you to our key sponsors

Main Sponsors

Cardiff and Vale University Health Board is one of the largest NHS organisations in Wales, employing approximately 14,000 staff and providing health services to a population of around 472,400 people living in Cardiff and the Vale of Glamorgan. They also serve a wider population across South and Mid Wales for a range of specialties. Their vision is to create a community where a person’s chance of leading a healthy life, is the same wherever they live and whoever they are. They are a teaching Health Board with close links to the University sector, and together we are training the next generation of healthcare professionals, while working on research that will hopefully unlock the cures for today’s illnesses.

Silver Sponsors

Cancer Research Wales is committed to reducing the impact of cancer on the people of Wales through supporting world-class cancer research in the areas of cancer prevention, early diagnosis and better treatments. Cancer Research Wales annually spends over £1.5M on research in Wales and currently funds over 40 different oncology-related research projects across the Principality.
# Contents Page

**Sponsors for CUKC 2015** 2

**Welcome from the CUKC 2015 Chairman, Professor Riordan** 4

**Welcome from the CUKC 2015 Co-Chairs**
- Welcome from the CUKC 2015 Co-Chair, Professor Lu 5
- Welcome from the CUKC 2015 Co-Chair, Professor Ji 6

**Welcome to Wales**
- Welcome from Wales’ First Minister, RT Hon Carwyn Jones, AM 7
- Welcome to Cardiff – Capital City of Wales 8-9

**Chairs and Committee Members** 10-11

**Senior Advisors** 12

**Cardiff - China Partnership** 13
Introduction to the Cardiff - China Partnership 14
- Cardiff China Medical Research Collaborative (CCMRC) 15

Introduction to the partners:
- Cardiff University 16
  - The College of Biomedical and Life Sciences, Cardiff University 17
- Capital Medical University (CMU) 18
- Peking University and Peking University Cancer Hospital and Institute 19
- Yiling Group and Yiling Medical Research Institute 20

**Key Note Speakers** 21
- Welcome Addresses 22-24
- Plenary, Evening Reception and Closing Sessions 25-29

**Breakout Session Speakers, 2a – 5c** 30-64

**Our history in pictures** 65
- Building joint research structures (2012 – 2014) 69-73
- Mutual visits and recognition (2010 – 2015) 74-78
- Scholarships, students and scholars (2009 – 2015) 79-85
- Joint conferences (2012 – 2014) 86-88
- The ‘Cardiff China Medical Alumni Association’ (2012 – 2014) 89

**Participating organisations** 90-91
Welcome from the CUKC 2015
Chairman, Professor Riordan

Dear Distinguished Guests, Friends and Colleagues,

On behalf of Cardiff University, I would like to extend a very warm welcome to everyone attending the China – UK Cancer (CUKC) Conference, 2015. I am privileged to introduce and open this conference in our beautiful Welsh capital city of Cardiff.

Cancer remains a major global health challenge, with over 14 million new cases and eight million deaths each year world-wide. Cancer does not recognise boundaries or geographical frontiers.

Overcoming such an enormous challenge requires a collaborative, multi-faceted approach. This conference will provide an international platform to discuss the priority area of cancer and its research and treatment.

Cardiff University exists to create and share knowledge and to educate for the benefit of all. Working collaboratively has always been a priority for Cardiff University. In the field of medical research, and in particular cancer research, this approach has led to the development of partnerships between Cardiff University and some of China’s leading cancer organisations.

Cardiff University has a long track record of working successfully with China. We are honoured to host this important international conference with our long term partners, Capital Medical University, Peking University and Yiling, who together form the Cardiff China Medical Research Collaborative (CCMRC).

CCMRC, an award winning collaboration, brings together world-class researchers to enhance the understanding of the molecular basis, diagnosis, prevention and treatment of cancer through joint research publications and student/scientist exchanges. Cardiff University is delighted with the formation of the Joint Research Centres and the highly successful China Medical Scholarship programme. In 2013, I was truly honoured to have been conferred with a prestigious Honorary Professorship by Peking University and also appointed as International Advisor by Capital Medical University.

Cardiff University’s mission in the battle against cancer requires the continuation and strengthening of our work with our Chinese partners which will bring mutual and tangible benefits to both universities. We still have a long way to go, but over the last forty years Cardiff’s world-leading research has resulted in a doubling of long-term cancer survival rates in the UK.

The next two days will celebrate the successes of our partnership but it will also provide an important opportunity to renew our efforts to combat cancer. Understanding the healthcare systems in both countries will help highlight strengths and identify the key challenges both now and in the future. I hope you will enjoy this exciting conference where all our guests can benefit from the exchange of scientific and innovative ideas in cancer research as well as networking with colleagues. Thank you all for participating in CUKC 2015 and I look forward to CUKC 2016 in China.

Professor Colin Riordan BA PhD
President and Vice-Chancellor, Cardiff University

CUKC 2015 Chairman
Welcome from the CUKC 2015 Co-Chair, Professor Lu

Distinguished President and Vice-Chancellor Professor Colin Riordan, dear Professors, Colleagues, Students and Friends,

As the President of Capital Medical University (CMU), one of the host institutions of the China - UK Cancer (CUKC) Conference 2015, I hope, on behalf of all the research fellows, teachers and students of CMU, that CUKC 2015 is a complete success. Also, as a Co-Chair of this conference, I would like to give my warm welcome and sincere thanks to all the scholars, teachers and students who are in attendance at this conference which is being held in Cardiff, the capital city of Wales, in the most beautiful season of the year!

CUKC is jointly held by Cardiff University and its Chinese partners once a year with the aim of providing an opportunity for researchers and scholars in oncology to communicate, exchange, and share their knowledge so as to promote development and advances in this area of research. CUKC is one of the biggest achievements of the collaboration between Cardiff University and China. CUKC 2014 was held in CMU, Beijing. The conference introduced young CMU scholars and students to cutting edge techniques and research developments in oncology in the UK. Equally, it introduced the clinical and scientific development in cancer research in China to the visiting UK scholars. CUKC facilitates and deepens the collaboration between China and the UK with a focus towards fighting cancer.

Since the initial collaboration between the two universities in 2006, with the support of the Cardiff and China Medical Scholarship, more than 40 young CMU scholars and doctors, who specialise in oncology, have joined the research training programme at Cardiff University under the supervision of Professor Wen G. Jiang. More than 50 research articles have been published during their time in Cardiff. Similarly, more than 20 medical students from Cardiff University have been to CMU on the student exchange programme. The two universities collaborate on research projects in oncology and have established one Joint Bio-medical Research Centre based in both CMU and Cardiff University. Notably, the collaborative laboratory based in CMU is recognised and supported by the Beijing Government as a Key Laboratory and is identified as an International Science and Technology Cooperation Base in Oncology.

I believe CUKC will further promote important studies and the communication of oncology research between these two universities. I hope CUKC can become a worldwide, influential academic platform for oncology research. Finally, I hope CUKC can achieve even more success this year!

Professor Zhaofeng Lu MD
President, Capital Medical University
CUKC 2015 Co-Chair
Welcome from the CUKC 2015
Co-Chair, Professor Ji

Distinguished Guests, Friends, Colleagues, Ladies and Gentlemen,

On behalf of Peking University School of Oncology, and together with our partners and co-organisers, Cardiff University, Capital Medical University and Yiling Group, I would like to warmly welcome you all to the China - UK Cancer (CUKC) Conference 2015, here in the beautiful and cultural city of Cardiff.

Cancer is a key health issue in China, UK and worldwide. It has become the leading cause of death in China, taking away millions of lives each year and causing a tremendous burden to the healthcare system. There remains huge gaps in our understanding of cancer development and progression, and effective approaches to cancer diagnosis and treatment are far from satisfying. It is well recognised that addressing these enormously resource-consuming challenges is beyond any single institution or country’s capacity. Thus Peking University, as one of China’s top centres for teaching and research, has been actively seeking worldwide collaboration with those dedicated to cancer research, prevention and treatment.

Cardiff University is one of the most creative, aspiring and thriving universities in the UK. It enjoys a high international reputation, especially in cancer research. Peking University’s partnership with Cardiff University dates back to 2001 when an agreement on scholar exchange was reached, and has expanded rapidly ever since. In 2007, Peking University Health Science Center established a formal relationship with Cardiff University after signing a Memorandum of Understanding. In 2012, the Cardiff University–Peking University School of Oncology Joint Institute was created, marking an important milestone. By combining our strengths in the new institute, several ambitious research projects including cancer diagnosis, treatment, new technologies and clinical trials have started. Fruitful outcomes include scholar exchange, joint research publications and novel technologies.

2015 is an important year for the China-UK cultural exchange. It promises to be a flagship year for the UK in China and for China in the UK. The two countries are trying to take this unique opportunity to further deepen and strengthen their existing relationship. Under these favourable circumstances and based on our solid friendship with our dedicated partners, we will endeavour to push the collaboration in the fight against cancer to a whole new level. I hope you all enjoy this conference and find it both interesting and informative. I also hope it is not only a grand event for academic exchange, but also a great opportunity to share our philosophy and values, strengthen mutual trust and further expand our partnership.

Thank you all.

Professor Jiafu Ji MD
President, Peking University Cancer Hospital and Institute
CUKC 2015 Co-Chair
Dear Chair and Conference Guests,

On behalf of Welsh Government, I welcome you all to the China – UK Cancer (CUKC) Conference 2015 which is being hosted in the heart of our beautiful capital city, Cardiff. It is a great pleasure to be part of this two day event which welcomes guests from across the UK and China.

It is a delight to see the impact of partnership working across international borders where institutions are joined by a shared ambition and willingness to tackle cancer; this fits with our over-arching policy framework in Wales called ‘together for health’.

A diagnosis of cancer is a major event in the lives of increasing numbers of people; with the most commonly diagnosed cancers being breast, bowel, prostate and lung. Despite overall health improving, with our ageing population, the demand for cancer care is increasing. Over the coming years in the UK, around 1 in 3 people will be diagnosed with cancer before age 75 and around 4 in 10 at some stage during their lifetime. In Wales, cancer is one of the two biggest causes of premature death and more than 18,000 people are diagnosed with the disease every year. Cancer accounts for nearly 7% of all NHS expenditure in Wales, reaching a record high at £360.9m in 2012-13. One of the challenges we face is the financing of the NHS and therefore we need to ensure we get the maximum value and impact from our cancer services.

The Welsh Government has set out a Cancer Delivery Plan, which acts as a framework for tackling cancer in Wales to 2016. We recognise the need to shift emphasis from just treating the illness, to promoting and protecting health by creating a culture of positive lifestyle choices. It is estimated that more than 4 in 10 cancer cases could be prevented by lifestyle changes but variation in the social determinants of health leads to wide and entrenched health inequalities, both in Wales and globally. Therefore, cancer has a greater impact on the more deprived parts of the population.

The Cancer Delivery Plan is being taken forward in a collaborative approach by NHS Wales, reflecting the co-productive and prudent healthcare principles elaborated by the Minister for Health and Social Services. The plan seeks to overhaul cancer services by raising screening rates, diagnosing people at earlier stages, developing primary care oncology, making cancer pathways more efficient, giving access to latest radiotherapy techniques and ensuring the growing number of cancer survivors is supported. It also highlights the importance of research, which is critical to effective cancer care and attracting investment. Wales has an excellent research reputation for cancer care which results in ongoing improvements in patient outcomes, access to novel therapies and the on-going implementation of evidence-based best practice. A strong research base stimulates opportunities for innovation, increasing the competitiveness of Welsh applications for grants from UK funding bodies and industry and supports the establishment of state of the art research units and centres.

There is wide recognition that much has already been achieved in Wales. Wales has shown the biggest improvement in cancer survival in the United Kingdom since 1993. Cancer services in Wales are better organised and better placed to deliver effective care than ever before. NHS Wales treats 12% more cancer cases now than in 2004; at the end of 2009 almost 85,000 people were living after a prior diagnosis of cancer during the previous 15 years or just under 3% of the population. Moreover, services have improved, data standards are now embedded in the clinical community and new drugs and technologies have been introduced. In September 2014, Wales became the first and only country in the UK, to make the new pancreatic cancer drug Abraxane available to all eligible patients on the NHS.

There has been considerable progress in cancer care in Wales over the past 12 months. We have now established firm foundations for further positive development. This is a tribute to all those involved in the planning and delivery in this important area. Working together against cancer, we can do even better. We need to meet the expectations of people with cancer. Everyone has a role to play; the Welsh Government, the NHS, local government, cancer charities, and the public. Wales is at the forefront of the global search for a cure for cancer and we aim to match the leading global healthcare services to promote and protect the health of people in Wales by delivering high quality cancer services. There is still a tremendous amount to be done in Wales and together we must do more to fight this battle.

I am delighted that such a prestigious UK – China event is being held in Wales. Not only is it a valuable contribution to the UK – China relationship, but it is another link in the increasingly strong and active relationship that is developing between Wales and China, something to which I attach great importance. On behalf of Welsh Government, we wish CUKC 2015 every success and we look forward to the long and fruitful future of the collaboration.

RT Hon Carwyn Jones, AM
First Minister of Wales
Welsh Government
Welcome to Cardiff – Capital City of Wales

Cardiff is the largest city in Wales and is located just two hours by train from London, with excellent road networks and its own airport. Cardiff is a city proud of its culture, history and language. Over the last 2000 years, the city has undergone a fascinating journey; progressing from a small settlement, to the world’s busiest port, to a modern capital city. In 2014, Cardiff was ranked the UK’s number 1 city according to the 2014 MoneySuperMarket research, based on a range of social and economic indicators:

“Of the 12 cities surveyed, the average cost of living was lowest in Cardiff, at £359 a week. The Welsh capital had one of the lowest unemployment rates at 8.1% and recorded the second-highest growth in disposable income (3.7%) when compared to last year’s survey, in which it placed third overall.”

Cardiff became a city in 1905 and was proclaimed the capital of Wales in 1955. The area around Cardiff has been inhabited for several thousand years. Early Bronze and Iron Age sites are dotted over the countryside and the Romans built an extensive fort near the mouth of the River Taff in 75AD. When the Normans arrived, they used parts of the old Roman walls in their building programme and these early Roman walls can still be seen. Considerable investment and a concerted building programme during the 18th and 19th centuries during the industrial era, resulted in the beautiful civic centre we see today.

Over recent years Cardiff has seen significant development which has led to it becoming a major tourist destination with around 19 million visitors a year. City council Leader Phil Bale, said: “Cardiff has been reinvented over the past 20 years through sustained investment, with a focus on sporting, cultural and leisure infrastructure.”

Known as one of the greenest cities in the UK, the city has more than 330 parks, gardens and peaceful spots. Across the city, innovative architecture sits alongside ancient historic buildings with most places easily accessible by walking or cycling. Cardiff is plentiful in attractions, quality shopping and top class entertainment and activities. The city centre offers a huge variety of shopping with a range of indoor, outdoor, old, modern, high street and designer shopping. The Millennium Stadium, home to many sporting achievements, is a prominent site in the heart of the city. Thriving Cardiff Bay offers entertainment for everyone from the Doctor Who experience, through to White Water Rafting, nestled amongst iconic buildings such as the Senedd for the National Assembly of Wales and the Wales Millennium Centre Arts complex, which welcomes more than a million people every year. Cardiff is renowned for being vibrant, friendly and accommodating to all tastes and budgets.
Chairs and Committee Members

**Conference Chairman:**
Professor Colin Riordan  
*Cardiff University*

**Conference Co-Chairs:**
Professor Zhaofeng Lu  
*Capital Medical University*
Professor Jiafu Ji  
*Peking University Cancer Hospital and Institute*

**Senior Advisory Committee:**
Professor Dylan Jones  
*Cardiff University*
Professor Nora de Leeuw  
*Cardiff University*
Professor John Bligh  
*Cardiff University*
Professor Adam Cairns  
*Cardiff and Vale University Health Board*
Academician Yiling Wu  
*Yiling Medical Research Institute*
Professor and Academician Shujun Cheng  
*Chinese Academy of Science*
Professor Xiaomin Wang  
*Capital Medical University*
Professor Qi Zhou  
*Chongqing Cancer Hospital*
Professor Jun Zhu  
*Peking University Cancer Hospital and Institute*

**Organising Committee:**

**Chair:**
Professor Wen G. Jiang  
*Cardiff University*

**Co-Chairs:**
Ms Rachel Hargest  
*Cardiff University*
Professor John Chester  
*Cardiff University*

**Committee Members:**
Professor Wei An  
*Capital Medical University*
Juliet Davies  
*Cardiff University*
Ceri Frayne  
*Cardiff University*
Dr Stephen Hiscox  
*Cardiff University*
Professor Malcolm Mason,  
*Cardiff University*
Professor Chris Pepper  
*Cardiff University*
Professor Jianli Xu  
*Shijitian Hospital, Capital Medical University*
Professor Xiuyi Zhi  
*Xuanwu Hospital, Capital Medical University*

**Secretariat Committee:**

**Chairs:**
Juliet Davies  
*Cardiff University*
Ceri Frayne  
*Cardiff University*

**Committee Members:**
David Yi Feng  
*Cardiff University*
Dr Edison Ke Ji  
*Cardiff University*
Hayley Spavin  
*Cardiff University*
Scientific Committee:

Honorary Chair:
Professor Sir Martin Evans
Cardiff University

Chair:
Professor Malcolm Mason
Cardiff University

Co-Chair:
Dr Stephen Hiscox
Cardiff University

Committee Members:
Dr Jun Cai
Cardiff University
Dr Yuxin Cui
Cardiff University
Professor John Darling
University of Wolverhampton
Dr Dafydd A. Dart
Cardiff University
Professor Wei Ding
Capital Medical University
Professor Zhenguo Han
Jilin University
Professor Chunyi Hao
Peking University
Ms Rachel Hargest
Cardiff University
Professor Junqi He
Capital Medical University
Professor Daqing Ma
Imperial College London
Dr Tracey A. Martin
Cardiff University
Professor Chuan Mi
Peking University
Professor Paul Morgan
Cardiff University
Professor Ruth Muschel
University of Oxford
Dr Andrew Sanders
Cardiff University
Professor Lin Shen
Peking University

Scientific Committee Members Continued:
Professor Weiguang Wang
University of Wolverhampton
Dr Zhidao Xia
Swansea University
Professor Jun Yang
Qingdao Medical University
Dr Lin Ye
Cardiff University
Professor Lu-Gang Yu
University of Liverpool
Professor Nengwei Zhang
Shijituan Hospital, Capital Medical University
Professor Zhongtao Zhang
Beijing Friendship Hospital, Capital Medical University
Professor Yanjun Zhu
Airforce General Hospital

Science Editor:
Dr Tracey A. Martin
Academician Yiling Wu’s professional distinctions include Academician of the Chinese Academy of Engineering, President of the Hebei Academy of Integrative Chinese and Western Medicine and founder of the Discipline of Collateral Disease Theory in Practice. He is Chief Scientist for two national natural science foundation projects and is the Head of the Key Laboratory of Collateral Diseases, State Administration of Traditional Chinese Medicine. Academician Wu is Vice-Chairman of the Chinese Association of the Integration of Traditional and Western Medicine and the China Association of Chinese Medicine. He is Director of the Collateral Disease Branch, China Association of Chinese Medicine, Director of the Vessel-Collateral Specialty Committee, Chinese Association of the Integration of Traditional and Western Medicine and Director of the Collateral Disease Specialty Committee, World Federation of Chinese Medicine Societies.

Professor Cheng is a well-known cancer researcher and cancer etiologist. He is a research fellow at the Cancer Institute and Hospital of Chinese Academy of Medical Sciences and an academician of the Chinese Academy of Engineering. Academician Cheng served as the Deputy Director of the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences between 1992 and 2001. Currently, he is an executive member of the Academic Committee in Chinese Academy of Medical Sciences and Peking Union Medical College. He is Chairman of the Chinese Environmental Mutagen Society and the Associate Chairman of the Chinese Anticancer Association. Academician Cheng has been awarded several national-level grants such as funding from national “75”, “85”, “95” five-year plan, and has established the advanced biological systems for testing mutagens and carcinogens. As early as 1987, he established a serum-free culture system which has been used for growing human epithelial cells in order to study the mechanism of carcinogenesis. He has carried out research projects on molecular mechanisms and biomarkers of lung cancer for more than 30 years. Significantly, he has made important advances in natural anti-carcinogen screening research and discovered that green tea catechins are effective for the treatment of Genital Warts caused by the human papilloma virus (HPV), which has been approved for international patent application. This special extract has been approved as a new prescription drug by the United States FDA in 2006. This is the first time that the United States has approved a complex composition of herbal medicine as a prescription drug in over 50 years. Academician Cheng also currently serves as Chairman of the Department of Medical Oncology, Capital Medical University, and the Academic Committee of Beijing Key Laboratory for Cancer Invasion and Metastasis Research, Cancer Institute of Capital Medical University.

After training at the universities of St Andrews and Manchester, Professor Bligh worked briefly in Bangor as a PRHO in general medicine. He was a general practitioner in Chester for 11 years before joining the University of Liverpool as, firstly, a Senior Lecturer then Professor of Medical Education and Head of the Department of Health Care Education. He was one of the foundation professorial staff of the Peninsula Medical School in the far South West of England for 10 years before joining Cardiff University as Dean of Medical Education in 2010. Professor Bligh was appointed Dean of Medicine and Head of the School of Medicine at Cardiff in January 2014. Professor Bligh was Editor in Chief of the journal, Medical Education (1997-2005) and was the inaugural President of the Academy of Medical Educators (2008-2010). He gave the William Pickles Lecture at the Royal College of General Practitioners in May 2012. He has published over 100 papers in leading international journals and is co-author of ‘Medical Education for the Future: Identity, Power and Location’ published in 2010 by Springer.
Cardiff - China Partnership
Introduction to the Cardiff - China Partnership

Cardiff University has enjoyed a long relationship with China. However, the past decade has witnessed a greater effort in the development of collaboration in the fight against cancer; in research, education, healthcare and indeed, in other health and social related sections in cancer care.

Cardiff University has particularly enjoyed strong partnerships with Capital Medical University, Peking University and Yiling Group, which cover broad areas of research; R&D to medicines and healthcare. These links have resulted in some fruitful outcomes, from student/scientist exchanges, joint research publications, new diagnosis, and new medicines.

The partnership history dates back to 1997. Ten years later the partnership activity accelerated with a series of key events, which in 2014 resulted in the launch of the Cardiff China Medical Research Collaborative (CCMRC), which brought together the four partners.

**2007**
- Cardiff University established the China Medical Scholarship, funded by generous gifts from Albert Hung and Henry Fong of Hong Kong and from 2013, by Yiling Wu of China.

**2010**
- Cardiff’s Vice-Chancellor, Dr David Grant was named ‘International Advisor’ for CMU at the Great Hall of the People, Beijing.

**2011**
- Cardiff University received the TIMES Higher Education ‘International Collaboration of the Year’ Award 2011 for work with China. Madam MeiYing Zhang, the Vice-Chairwoman of the National Committee of the Chinese People’s Political Consultative Conference called the partnership a ‘shining example of the Sino-UK scientific collaboration’.

**2012**
- Cardiff University-Peking University School of Oncology Joint Institute was launched and a Memorandum of Understanding (MoU) signed between the two institutions.

- Cardiff University – Capital Medical University Joint Centre for Biomedical Research was established.

**2013**
- Cardiff University – Yiling Group Joint Centre for Medical Research was established.

- Peking University conferred the Honorary Professorship on Cardiff University’s President and Vice-Chancellor, Professor Colin Riordan at the International Centre of Peking University Health Science Center, hosted by Professor Yang Ke: “to recognise Professor Riordan’s marvellous achievement in humanity, social science, education and efforts in promoting the mutual understanding and collaboration between Peking University and Cardiff University”.

- MoU signed between Cardiff University and Capital Medical University to facilitate education, focus collaboration and set a framework for the exchange of students.

**2014**
- The Cardiff China Medical Research Collaborative (CCMRC) was established, based at Cardiff University.
Cardiff China Medical Research Collaborative (CCMRC)

College of Biomedical and Life Sciences, Cardiff University

The Cardiff China Medical Research Collaborative (CCMRC) is based in the School of Medicine under the College of Biomedical and Life Sciences in Cardiff University. CCMRC brings together the four partners; Cardiff University, Capital Medical University, Peking University and Yiling Group with the aim to further research into cancer.

CCMRC represents an internationally renowned cancer research team whose research focus concerns basic and translational studies relevant to many forms of cancer including breast, colorectal and lung tumours, with a view to providing better diagnosis, treatment and prevention of disease.

CCMRC has many successful collaborations with academics worldwide. The vibrant research community has supported a number of projects, resulting in the creation of several spinout companies.

As well as providing opportunities for research, CCMRC supports the educational development of junior researches and academics, including undergraduate and postgraduate students and clinical fellows, through teaching activities, research studentships and clinical fellowships.

Since CCMRC was established, the China Medical Scholarship successes have continued. Over the past year, awards have included: China-UK Cancer Research International Collaboration Base (Beijing) with CMU, Key Laboratories of Cancer Invasion and Metastasis with CMU, awarded by the Beijing Government and the successful award of Natural Science Foundation research grants with Peking University.

Looking ahead, CCMRC will continue to focus efforts on cancer research, training, scholar exchange and grant funding to advance cancer research and treatment.

By combining the strengths of the four institutions, large scale research, education and trials in cancer and in other areas of medicine can be conducted.

The four partners will continue to Fight Cancer Together through the international collaborative.
Introduction to the partners

Cardiff University

Founded in 1883, Cardiff University is a world-leading, research-excellent, educationally outstanding university, driven by creativity and curiosity, which fulfils its social, cultural and economic obligations to Cardiff, Wales, and the world. Cardiff is ranked amongst the top 5 universities in the UK for research excellence and impact. We have won five Queen’s Anniversary Prizes and our researchers include two Nobel Prize winners - Professor Sir Martin Evans and Professor Robert Huber.

Our ambition as stated in our strategic plan, The Way Forward is to be consistently among the top 100 universities in the world and the top 20 in the UK by 2017. Our global community, reputation and partnerships are at the heart of our identity. We attract the highest calibre of academics and researchers from around the world, further enhancing the learning experience for students and bringing a wider perspective to our research.

Tackling global challenges through international partnerships

Our ambition is to form tightly knit collaborations with international universities in order to promote research, share best practice in teaching and management, and establish our position as a global university. We have formal links with more than 35 countries including 47 partnerships across China; 14 in Malaysia and 23 in the US. Our collaborative work with academic partners across the world produces research with real impact. From collaborating with researchers in China in order to tackle cancer, to studying the genetics and demographics of mammals in our research centre in Borneo, we’re working to tackle global challenges.

An international education

We have 28,540 students enrolled at Cardiff, representing over 100 countries.

- 21,020 undergraduates
- 7,520 postgraduates
- 5,885 international students

Cardiff University has links with over 250 top-ranked institutions across the world. A growing number of our students choose to undertake a placement abroad to study, work or volunteer as part of their Cardiff experience. This helps them build cultural awareness and enhance their employability. We also welcome hundreds of students on exchange programmes from countries across the world, from Latin America to Hong Kong.

A global alumni network

We have more than 180,000 alumni in over 170 countries around the world, from China to Chile. Our graduates return home as ambassadors for Cardiff University, Wales and the UK and often play an important role in developing good diplomatic and trade relations.
Introduction to the partners

The College of Biomedical and Life Sciences, Cardiff University

The College of Biomedical and Life Sciences brings together eight Schools with immense strength in research and teaching, not just in Wales, but the UK and worldwide. Our Academic Schools include:

- Biosciences
- Dentistry
- Healthcare Sciences
- Medicine
- Optometry and Vision Sciences
- Pharmacy and Pharmaceutical Sciences
- Postgraduate Medical and Dental Education
- Psychology

The College aims to be a world-leading centre of academic and clinical excellence, renowned for holistic, student-focused education and specialty training targeted at improving the health and well-being of society. An integrated approach is taken to all aspects of health and bio-scientific research, achieving internationally respected results at all stages of the medical research process, from laboratory science through to improved medical and healthcare practices.

Our Research Excellence and Research Themes

The College of Biomedical and Life Sciences played an important part in the REF 2014 results. Cardiff is officially 2nd in the UK’s for its world-leading research in psychology, psychiatry and neuroscience breaking the grip of the UK’s golden triangle of research intensive universities in these fields. From the discovery of a new bacteria resistant to antibiotics; creating new treatments for leukaemia, breast and prostate cancers; and improving dialysis treatment our world-leading research in clinical medicine has helped secure a ranking of 8th in the UK with 80 per cent deemed ‘outstanding’ for its impact in terms of its reach and significance. The same is also true of our research in health services and primary care. The sustained excellence of our research involving contributions from diverse areas including pharmacy, dentistry healthcare sciences, medicine, and optometry and vision sciences ranks us amongst the very best in the UK (4th).

The impact of our work is seen in a range of activities from the introduction of new therapies and diagnostics, leading change in practice and standards, through to advancing and informing public policy initiatives. Research excellence is also particularly noteworthy in Biological Sciences. From the understanding of precisely how neurons grow and the fundamental processes that underlie cancer development; to exploring the genetics of orang-utans, elephants, pandas and other endangered species.

The College of Biomedical and Life Sciences has formulated five broad research themes which will be the College’s primary research drivers, and will facilitate the development and integration of research across the full spectrum of the College’s activities; Cancer, Immunology, Infection and Inflammation, Mind, Brain and Neuroscience, Population Health and Biosystems. The research themes will enable the College to develop critical mass, coherence and scale in areas where Cardiff has the potential to be world leading, and to identify and grow research synergies.
Capital Medical University (CMU) was founded in 1960. It ranks amongst the top academic medical institutions in China and is considered to be one of the key municipal Universities in Beijing. CMU consists of ten schools, twenty affiliated hospitals and one teaching institution. The University has 10,132 enrolled students and offers a diverse spectrum of undergraduate, graduate, doctoral and specialised degree programmes to meet the varied needs of its students. It is purported to be the world’s largest medical University, with 20 affiliated hospitals and more than 16,500 hospital beds. It delivers a full range of health, medicine and life science related subjects at all levels.

Cardiff University and Capital Medical University (CMU) have enjoyed a long and fruitful relationship in research and education since 2003 and in 2012, the Cardiff University – Capital Medical University Joint Centre for Biomedical Research was established.

This Centre has created opportunities for research in a number of medical fields. In particular, research has been advancing on the metastasis of breast cancer examining how the disease spreads around the body. To date, our collaborative research has discovered new biomarkers for not only breast cancer but also for prostate and kidney cancer. Other research projects have focused on brain metastasis and gastrointestinal cancers. In future, the scope could expand to include areas such as neurology, dentistry, nursing and tissue repair.

Cardiff’s relationship with CMU has led to the introduction of a China Medical Scholarship. The scholarship has already supported more than 50 Chinese medics in the last 5 years to spend time in Cardiff for research training, clinical experience and education.
Introduction to the partners

Peking University and Peking University Cancer Hospital and Institute

Founded in 1898, Peking University is the top ranked University in China and one of the premier universities in the world. It is one of the top 5 Higher Education Institutions in Asia and its research, teaching and international activities are recognised worldwide for their excellence. It is also a leading cancer research and cancer service in China. Some of China’s leading cancer experts work at Peking University Cancer Hospital. Peking University Cancer Hospital physicians provide patient oriented medical services in a wide variety of cancer specialties treating gastric cancer, breast cancer, lung cancer, colorectal cancer, liver cancer, oesophageal carcinoma, lymphoma, melanoma, and much more.

The Cardiff University – Peking University Cancer Institute (CUPUCI) was established in 2013. Cardiff University has been collaborating with Peking University in Beijing for over a decade and has hosted a large number of their cancer scientists and specialists over the years. CUPUCI consists of two designated research centres, one located at each university. These centres provide a true home and state-of-the-art facilities for our Fellows and PhD students to collaborate more effectively. At Peking, the Institute is located in its nation’s renowned Peking University Cancer Hospital and Beijing Cancer Institute. Currently, the Cardiff – Peking Cancer Institute research focus is on some of the most aggressive forms of cancer, including gastrointestinal cancers, pancreatic cancer lung cancer and oesophageal carcinoma, which are amongst the priority areas in healthcare and cancer research in both the UK and China. Research work also concentrates on cancer metastasis, angiogenesis, biomarkers and new methods of cancer treatment, including alternative medicine such as traditional Chinese medicine.
Introduction to the partners

Yiling Group and Yiling Medical Research Institute

Yiling Group Medical Research Institute was formed in 1992 by Professor Yiling Wu, a highly accomplished scientist, medic, academician, entrepreneur and politician in China. Yiling Pharmaceuticals is one of China’s high-tech pharmaceutical companies, devoted to R&D, manufacture and marketing of new medicines. It has some unique approaches in therapeutic development for diseases such as arrhythmia, heart failure, bird flu and cancer.

Cardiff University has been collaborating with Yiling Group since 2011, initially investigating the potential mechanism(s) of some anti-cancer medicines. In 2013, the Cardiff University – Yiling Group Joint Medical Research Centre was established to focus on developing and advancing new treatments for cancer and infectious diseases, with a particular focus on Chinese medicine.

The team at Cardiff, along with colleagues at Peking University and the team at Yiling, have together been testing the health benefits of the Chinese herbal medicine in cancer treatment. Some of the herbal medicines had previously been shown to be beneficial to cancer patients but until this latest research, the way in which it worked had remained unknown. The joint research investigated how the herbal medicines worked and discovered that it blocks signalling pathways, reducing the spread of cancer cells in the body. The Chinese formula has been shown to be beneficial to patients with certain solid tumours, both when used alone and in conventional therapies, such as chemotherapy.

Cardiff’s collaboration with Yiling has also allowed the creation of new scholarship opportunities for Chinese medical scholars, enabling them to undertake study and training in the UK. Likewise, UK students will be able to gain overseas experience by spending time with Cardiff’s partners in China. By 2017, 17% of Cardiff University’s home students will have studied, worked or volunteered abroad for at least a month during their time at Cardiff. The Joint Centre, which focuses on translational and clinical research, will in future, look to extend the research collaboration to other areas of medicine in addition to cancer.
Key Note Speakers

Welcome Addresses
Plenary Session
Evening Reception
Closing Session
Welcome Addresses

Professor Colin Riordan took up the post of President and Vice-Chancellor at Cardiff University on 1 September 2012. Previously, he was Vice-Chancellor of the University of Essex, having been appointed in October 2007. He moved to Essex from Newcastle University, where he had been Pro Vice-Chancellor and Provost of the Faculty of Humanities and Social Sciences since August 2005. Professor Riordan taught English as a foreign language at Julius-Maximilians-Universität Würzburg in Germany (1982-84) and was Lecturer, then Senior Lecturer in German at Swansea University (1986-1998). He became Professor of German at Newcastle University in 1998, where he remained until his move to Essex in 2007. He has published widely on post-war German literature and culture, including editing books on the writers Jurek Becker, Uwe Johnson and Peter Schneider. Other research interests include the history of environmental ideas in German culture. He is a Vice-President of Universities UK and a board member of the Leadership Foundation for Higher Education, the Edge Foundation, UCAS and the Equality Challenge Unit. In 2013, he became Chair of Universities Wales, the body which represents the interests of Higher Education Institutions in Wales. He is also a member of the Cardiff Capital Region Board and sits on the Review of Higher Funding and Student Finance in Wales. As Chair of the UK Higher Education International Unit, he is active in promoting and advancing the role of UK universities aboard. He is a member of the International Education Council sponsored by the Department of Business, Innovation and Skills and, in 2014, he became a Fulbright Commissioner.

Carwyn Jones was born in 1967. He was educated at Brynteg Comprehensive School, Bridgend, University of Wales Aberystwyth and Inns of Court School of Law, London. He has been a Labour Party member since 1987 and the Assembly Member for Bridgend since 1999. Between March 2000 and December 2009 he held a number of different ministerial portfolios. Following the retirement of Rhodri Morgan AM, he was appointed First Minister of Wales on 9 December 2009 and was appointed to the Privy Council on 9 June 2010. Following the Assembly Elections in May 2011 he was re-appointed First Minister of Wales.

Welcome Addresses

Professor Ji is the President of Peking University Cancer Hospital and Institute. He also serves as Vice-President of the Chinese Anti-Cancer Association and President-Elect of the Cancer Hospital Management Association, an organisation which is a champion of health care improvement based on changes by professionals in China. Professor Ji has also served as Director of the International Cooperation Department of the China Medical Association. Professor Ji is one of the leading pioneers on healthcare quality and improvement and is renowned for his experience in changing health care practices for the better. A gastrointestinal surgeon by background, Professor Ji has served as a distinguished clinical Professor of gastrointestinal surgery at the Peking University Cancer Hospital for almost thirty years, and was subsequently appointed the position of President of the Hospital. Under Professor Ji’s leadership, Peking University Cancer Hospital has been selected as the “Top International Cancer Centre in China”, adopting advanced strategies to optimise treatment and make a difference in patient care. Professor Ji is internationally recognised for translational and clinical research in cancer. He is the President of the International Gastric Cancer Conference 2017 and President of the Chinese Gastric Cancer Association. Under his leadership, innovative training programmes in the forms of gastric surgery demos and itinerant lectures have benefited thousands of surgeons on the standardised management of gastric cancer. His scientific programme has made fundamental discoveries, both in fruitful basic research and international multi-center clinical trials. With unique vision, Professor Ji took the lead in constructing a bio-bank of cancer in China. The biggest bio-bank of cancer in China has remarkably promoted the knowledge and expertise of this bio-bank construction for research.

Professor Lu is the President of Capital Medical University, China. After studying in Beijing Medical College, he has worked as a doctor, educator, officer, as well as a researcher in medicine and medical education over the past 30 years. He is a rigorous and conscientious educator who works hard and is diligent in his thinking and research. He has notable achievements in the research of Clinical Pathology, Comparative Medical Education and Higher Medical Education, which has won high remarks among peers. Over the years, he has presided over the project of Higher Education reform, supported by the World Bank, which promotes the reform of CMU’s Higher Medical Education in teaching. He has also led several teaching reform projects, supported by the Ministry of Education, the Ministry of Health and the Beijing Municipal Government, all of which have achieved great results.
Welcome Addresses

Professor Xiaomin Wang
Vice-President, Capital Medical University

Professor Wang received his undergraduate training and got his BA from the Department of Medicine, Chinese Medical University in China in 1982. He got his MS from Dalian Medical University in China in 1988. He undertook joint training between Beijing Medical University in China and Munich University in Germany and got his PhD in 1993 from Beijing Medical University. He is now the Vice-President of Capital Medical University and a member of the International Brain Research Organization (IBRO) and European Neuroscience Association. He was the Deputy Director of the Neuroscience Research Institute, Beijing Medical University; Deputy Dean and Dean of School of Basic Medical Science and School of Telemedical Education, Peking University; President of Beijing Society for Neuroscience (2000-2008) and Vice-President of Chinese Society for Neuroscience (2002-2010). He is the editor in chief of Translational Medicine Research and Journal of Capital Medical University and associate editor in chief of the Chinese Journal of Neuro-medicine, Journal of Basic – Clinical Medicine and British Medical Journal (Chinese edition). He is a Council Member of the Federation of the Asian and Oceanian Physiological Societies (FAOPS), International Union of Physiological Sciences (IUPS) and International Society for Biological and Environmental Repositories (ISBER). He has worked as a visiting scientist in the University of Munich, Germany, Rockefeller University, Indiana University and Cold Spring Harbor Laboratory, USA. His research interests include the mechanism and application of acupuncture and the neuroprotection of natural drug monomer and of inducible committed differentiation of neural embryonic stem cell and in situ stimulation of adult stem cell on in vivo models of Parkinson’s disease. In the past few years, his research has expanded into the pathogenesis of Alzheimer’s disease and the pharmacological application and mechanism of natural drug monomer on in vivo models of Alzheimer’s disease. As the Principal Investigator, 28 research projects have received funding. He has published more than 150 peer-reviewed papers (88 SCI papers) and has filed 6 patents on monomer compounds of potential drugs isolated from natural products in China. He is also a Chief Scientist of the National Key Basic Research Programme for Parkinson’s and Alzheimer’s disease.

Mr Shen Yang
Minister Counsellor for Education, Chinese Embassy, UK

Mr Shen Yang was born on November 7, 1959 in Zhejiang, China. He was educated in both China and Britain. He was an English language student in the Shanghai Foreign Languages Institute (1971-81), before studying English Language in the UK under the Chinese Government Scholarship Programme at the Polytechnic of Central London (1981-82) and Applied Linguistics at the University of Durham (1982-83). He was awarded a British Government China Senior Scholarship (Chevening Scheme) to study for his Master’s degree in Higher Education Administration and Management at the University of Manchester (1989-90). Mr Shen joined the Ministry of Education in 1983. Over the past 30 years, he has worked in the area of international cooperation and exchanges in education. He started as a programme officer and UK desk officer in the General Affairs Division and later moved into the European Division of Foreign Affairs Bureau of the Ministry of Education (which became State Education Commission between 1986 and 1998). He served as Deputy Director of the European Division of the Department of Overseas Studies of State Education Commission (1992-93), and was appointed Director of the European Division of Department of Foreign Affairs (which was renamed Department of International Cooperation and Exchanges in 1998) in 1997. From August 2000 to February 2003, he was Deputy Secretary-General of the China Scholarship Council, and from August 2008 to March 2012, he served as Deputy Director-General of Department of International Cooperation and Exchanges of Ministry of Education. Mr Shen was appointed Minister Counsellor for Education of the Chinese Embassy in London in April 2012. He has previously been posted twice to the Chinese diplomatic missions in the United States: he was Second Secretary and then First Secretary in the Education Office of the Chinese Embassy in Washington DC (1993-1997); and he served as Education Counsellor in the Chinese Consulate General in San Francisco (2003-2008). The current assignment is his third tour of duty overseas.
Plenary, Evening Reception and Closing Sessions

Plenary Session Chair

Professor de Leeuw FRSC is Pro-Vice Chancellor, International and Europe, of Cardiff University, where she also holds a Royal Society Industry Fellowship in the School of Chemistry. Prior to her appointment at Cardiff University in 2015, she has held a lectureship at the University of Reading, an EPSRC Advanced Research Fellowship at Birkbeck College London and was Professor of Computational Chemistry and Director of the Industrial Doctorate Centre in Molecular Modelling and Materials Science at University College London, where she still holds a William Penney Fellowship awarded by AWE in 2014. Professor De Leeuw was awarded a Royal Society Wolfson Research Merit award in 2010, a visiting professorship at the University of Paris-Est in 2011, and she also holds a professorship in Theoretical Geochemistry and Computational Mineralogy at Utrecht University in the Netherlands. Her research is supported extensively by external funding from the UK Research Councils, EU, the Royal Society, Wellcome Trust and industry.

Plenary Session Speakers

Professor Sir Martin Evans FRS
Chancellor and Nobel Prize Laureate, Cardiff University

Professor Sir Martin Evans was the first scientist to identify embryonic stem cells, which can be adapted for a wide variety of medical purposes. His discoveries are now being applied in virtually all areas of biomedicine from basic research to the development of new therapies. In 2007, he was awarded the Nobel Prize for Medicine, the most prestigious honour in the world of science for "ground-breaking discoveries concerning embryonic stem cells and DNA recombination in mammals." Sir Martin gained his BA in Biochemistry from Christ College, University of Cambridge in 1963. He received an MA in 1966 and a DSc in 1966. In 1969 he was awarded a PhD from University College, London. He joined the Cardiff University School of Biosciences in 1999. Sir Martin has published more than 120 scientific papers. He was elected a Fellow of the Royal Society in 1993 and is a founder fellow of the Academy of Medical Sciences. He was awarded the Walter Cottman Fellowship and the William Bate Hardy Prizes in 2003 and in 2001 was awarded the Albert Lasker Medal for Basic Medical Research in the US. In 2002 he was awarded an honorary doctorate from Mount Sinai School of Medicine in New York, regarded as one of the world’s foremost centres for medical and scientific training. He has also received honorary doctorate awards from the University of Bath, University of Buckinghamshire, University College London, University of Wales and the University of Athens. He was knighted in 2004 for his services to medical science and in 2009 was awarded the Gold Medal of the Royal Society of Medicine in recognition of his valuable contribution to medicine. In 2009 he also received the Baly Medal from the Royal College of Physicians and the Copley Medal, the Royal Society’s oldest award, joining an eminent list of previous recipients including Albert Einstein.
Plenary Session Speakers

FP0102
*Strategies and controversy in the surgical treatment of gastric cancer*

Biography available on page 21

Professor Jiafu Ji
*President, Peking University Cancer Hospital and Institute*

Professor Qi Zhou
*President, Chongqing Cancer Hospital*

FP0103
*The status and prospect of screening and treatment of cervical cancer in China*

Professor Zhou is Chief Physician of Chongqing Cancer Hospital and doctoral advisor. Professor Zhou has worked in the gynaecological oncology field for 30 years, specialising in the diagnosis and treatment of gynaecological tumours and other gynaecological diseases, especially combination therapy for gynaecological malignancy. She has dedicated herself in the promotion of tumour screening and standardised treatment over the years. Her work also includes research in multidrug resistance mechanisms and early diagnosis of ovarian cancer. Academic participation includes standing director of the Chinese Anti-cancer Association; Chairman-elect for the Chinese Anti-cancer Association Gynecological Oncology Committee, Vice-Chairman of the National Cervical Cancer Consortium and China International Exchange and Promotion Association for Medical and Healthcare of Obstetrics and Gynecology and Chairman of the Chongqing Anti-Cancer Association Gynecological Oncology Committee.

FP0104
*Optimising surgical resection of colorectal cancer liver metastases*

Professor Poston is a consultant hepatobiliary surgeon at the UHA, Liverpool, UK, and Professor of Surgery in the School of Translational Studies of the University of Liverpool. He enjoys an international reputation in hepatobiliary surgery. To date, he has personally performed over 900 major hepatobiliary resections. His unit at UHA is one of the largest tertiary resectional hepatobiliary practices in the UK, having performed over 2,000 liver resections over the last 25 years. He gained his undergraduate medical training at St George’s Hospital Medical School, London, graduating in 1979, and received postgraduate training at The Hammersmith Hospital and St Mary’s Hospital, London, and University of Texas Medical Branch, Galveston, Texas. He is the Chair of the Editorial Advisory Board of the European Journal of Surgical Oncology and a past president for the European Society of Surgical Oncology, the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, and the British Association of Surgical Oncology. He is Chair of NHS HPB Specialised Commissioning, NHS England Specialised Commissioning Internal Medicine Programme of Care, NICE Colorectal Cancer Guideline Development Group and Quality Standards Committee, and past Chair of the Cancer Services Committee of the Royal College of Surgeons of England. He is the Principal Investigator of a number of ongoing national and international clinical trials in hepatobiliary surgery, and co-author of numerous national and international guidelines for the management of hepatobiliary cancers, nine textbooks of surgery, and over 220 papers. Honours and distinctions include the Ernest Miles Medal of the Royal Marsden Surgical Society, Olaf ac Acrel Medal of the Swedish Surgical Association, Stanford Cade Medal of the Royal College of Surgeons of England, Kilroe Medal of the Christie Hospital, Manchester, N K Misra Medal of the Indian Association of Surgical Oncology, Honorary Fellow of the Association of Surgeons of India and the College of Surgeons of Sri Lanka, Hunterian Professor of the Royal College of Surgeons of England, and numerous international visiting professorships. He enjoys trekking in high places including Kilimanjaro, Everest, Annapurna Base Camps, Kala Pattar and Lakya La.
Plenary Session Speakers

Biography available on page 22

Professor Xiaomin Wang
Vice-President, Capital Medical University

FP0106
The role of culture in improving cancer services in a time of austerity

Professor Cairns has spent over thirty years in health care management and leadership roles in the English NHS. He worked for ten years at board level in the Leeds Teaching Hospitals NHS Trust before becoming Chief Executive of Airedale NHS Foundation Trust. During his tenure at Airedale, the Trust was ranked by Dr Foster as the best performing local District General Hospital in England for four consecutive years. Following a period in Shropshire as Chief Executive of Shrewsbury and Telford NHS Trust where he led a significant strategic change programme, he moved to Wales as Chief Executive of Cardiff and Vale UHB in July 2012. Cardiff and Vale UHB is an organisation employing 14,000 people and with a budget of £1.2bn aims to drive improvements in population health as well as providing mental health, primary, community, secondary and tertiary hospital care services to its local population and the wider population of South Wales. He was awarded the title of Honorary Visiting Professor in Cardiff Medical School in November 2014.
Evening Reception Speakers

Professor Dylan Jones OBE
BSc (Tech) PhD DSc Wales
AcSS FBPsS
Pro Vice-Chancellor, College
of Biomedical and Life
Sciences, Cardiff University

Professor Jones plays a key role in setting the strategy and direction of the College and in promoting the development of learning, teaching and research excellence. As Pro Vice-Chancellor, Professor Jones is also a member of the University Executive Board. Formerly Head of the School of Psychology, he played a leading role in establishing the School as one of the largest and best in the UK. This included establishing the Cardiff University Brain Imaging Centre (CUBRIC) and drawing funds for Wales Autism Research Centre (WARC). A graduate of UWIST, Professor Jones did his research training with Donald Broadbent FRS at the University of Oxford. Early in his career he qualified as an Occupational Psychologist, and from a university base he engaged in research with a range of public sector and private organisations. Research areas were in sectors as diverse as aviation and nuclear safety, postal services, advertising and industrial design. More recently, he has focused his research on his interests in human experimental psychology researching on topics related to short-term memory and attention. Much of his work on attention relates to the distraction caused by sound. He has an active research group who are currently drawing funds from projects with the Economic and Social Research council and with the Swedish Government. He is author of over 200 journal publications, including six edited books and has supervised some forty PhD students.

Professor Mark Drakeford
AM
Minister for Health and Social Services, Welsh Government

Professor Drakeford was born and brought up in West Wales before moving to Cardiff more than 30 years ago. Since then he has lived in the Pontcanna area of Cardiff. A former probation officer, youth justice worker and Barnardos project leader in Ely and Caerau, he has been a Professor of Social Policy and Applied Social Sciences at Cardiff University. He has also taught previously at Swansea University. In the 1980s and 1990s he was a Labour Councillor on the South Glamorgan County Council, specialising in education issues, including Welsh medium education. Between 2000 and 2010 he worked as the Cabinet’s health and social policy adviser at the Welsh Government, and was latterly Head of the First Minister’s political office. He has 30 years knowledge of the Cardiff West constituency. He became the Assembly Member for Cardiff West in May 2011. He was Chair of the Assembly’s Health and Social Care Committee from July 2011 - March 13 and of the All-Wales Programme Monitoring Committee for European funds from July 2011 – March 13. He was appointed Minister for Health and Social Services in March 2013.
Closing Session Speakers

Professor Wen G. Jiang is Professor of Surgery and Tumour Biology at Cardiff University School of Medicine. He is currently Dean of International, and Director of Cardiff’s China Medical Research Collaborative (CCMRC) and Director of the Cardiff University-Peking University Cancer Institute of Cardiff University. Professor Jiang received his primary degree in clinical medicine from Peking University Health Science Centre and his MD from Cardiff University, where he practised surgery and subsequently became Chair of Surgery and Tumour Biology in 2004. Professor Jiang’s main research interest is in cancer and cancer metastasis and over the past two decades has conducted research at basic, translational and clinical aspects of the disease. He is a Fellow of the Royal Society of Medicine and Fellow of the Royal Society of Biology.

Professor Malcolm Mason
Dean of Research, College of Biomedical and Life Sciences, Cardiff University

UK clinical research in prostate cancer: driving change in medical practice worldwide

Professor Mason is the Cancer Research Wales Professor of Clinical Oncology, and Dean of Research in Life Sciences and Health at Cardiff University. He graduated from St Bartholomew’s Hospital in London, and trained in oncology at the Institute of Cancer Research and Royal Marsden Hospital. He is the current Chair of the UK National Cancer Research Network Prostate Cancer Clinical Studies Group. He has been responsible for several practice-changing national and international clinical trials in cancer, most notably the recent intergroup study which demonstrated that radiotherapy could halve the mortality from locally advanced prostate cancer. He is the Director of the Wales Cancer Bank, the first national population-based tumour bank to be launched in the UK. He also works for the Union for International Cancer Control on their TNM programme for cancer staging, for which he is the Co-Chair of the Process Task Force, a member of the Core Group, and the Chairman of the UK National TNM Committee.

Dr Fergus Macbeth MA DM FRCR FRCP MBA
Biography available on page 24

SC0602
Getting cancer research into practice: The role of NICE

Dr Macbeth is a retired oncologist with a long standing clinical and research interest in lung cancer. He is Coordinating Editor of the Cochrane Lung Cancer Review Group and Associate Director of the Wales Cancer Trials Unit, Cardiff. He worked for the National Institute for Health and Care Excellence (NICE) for 10 years, most recently as Director for the Centre for Clinical Practice, responsible for NICE’s clinical guidelines and quality standards programmes. He is currently mentor to NICE Fellows and Scholars, chairs the NICE guideline on melanoma and teaches for the UK Cochrane Centre.

Biography available on page 24

Professor Sir Martin Evans FRS
Chancellor and Nobel Prize Laureates, Cardiff University
Breakout session speakers

2a - 5c
Professor Hao completed his Master of Medicine degree at Beijing Medical University in 1993. From 1993 to 2000, he worked in the Department of Surgery at Beijing Cancer Hospital as a resident and attending doctor. In 2001, he received his doctor’s degree. From 2001 to 2003 he participated in a postdoctoral programme focusing on oncogenesis at the California Pacific Medical Center, U.S.A. In 2005, he was invited as a visiting professor to the Hepatobiliary Surgery Center of Hospital de Hautepierre, Louis Pasteur University (France) for half a year. In 2006, he was promoted to Chief Surgeon and in 2007, he was appointed Director of the department of HPB Surgery in the Beijing Cancer Hospital. In 2008, he became a Professor at Peking University, School of Oncology. From August to September 2008, he was an academic visitor to the Pancreatic Surgery Center of Johns Hopkins Hospital (USA). He currently works as the Deputy Chief of the Department of Surgery in Peking University Cancer Hospital and is the Director of the Department of Hepato-Pancreato-Biliary Surgery. His clinical and research activities focus on diagnosis and treatment of primary and metastatic hepatic carcinoma, cholangiocarcinoma, pancreatic cancer and retroperitoneal tumours. He is the pioneer of some delicate radical surgeries which aim to improve the resection rate of hilar cholangiocarcinoma and pancreatic cancer. He has promoted the new concept of colorectal liver metastases and related techniques, and developed the first multidisciplinary treatment guidelines for colorectal liver metastases in China. He was supported by the National Natural Science Foundation and participated in the pancreatic cancer genome study under the National High-tech R&D Programme. He established the first CME Center of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO) in China. He is the Beijing Health system Academic Leader in Hepato-Pancreato-Biliary oncological surgery and an Honorary Professor of Cardiff University (UK). He was appointed Deputy Secretary-General of IASGO, Chairman of the Pancreatic Cancer Committee of Chinese Society of Clinical Oncology (CSCO) and the Chinese Strategic Alliance of Technology Innovation in Minimally Invasive Tumour Therapy, and Vice-Chairman of the Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Committee of CSCO. He is also a faculty member of the International School of Surgical Oncology (ISSO), a member of the Fourth CSCO Executive Committee, the Beijing Oncology Society of Chinese Anticancer Association and the Chinese Geriatric Oncology Society. He is on the editorial board of several renowned medical journals at home and abroad.

Professor Chunyi Hao
Chief, Department of HPB Surgery, Peking University Cancer Hospital and Institute

FBO2A01
The role of calcium signalling in development of pancreatitis and pancreatic cancer

Professor Petersen is a Medical Research Council Professor at Cardiff University’s School of Biosciences. He was elected Fellow of The Royal Society (FRS) in 2000 and member of the German National Academy of Sciences Leopoldina in 2010. He received the Czech Academy of Sciences’ Purkyně Medal in 2003 and became Commander of the Order of the British Empire (CBE) in 2008. In 2013, he was awarded The American Physiological Society’s Horace W Davenport Distinguished Lectureship and delivered the Award Lecture at FASEB’s ‘Experimental Biology’ in Boston, USA. In 2014, he chaired the Biological Sciences Panel in the UK Government’s Research Excellence Framework.

Professor Ole H Petersen
CBE FRS
Medical Research Council Professor, Cardiff University

FBO2A02
Expression of CD26/DPPIV promotes growth and metastasis of pancreatic carcinoma

Professor Hao completed his Master of Medicine degree at Beijing Medical University in 1993. From 1993 to 2000, he worked in the Department of Surgery at Beijing Cancer Hospital as a resident and attending doctor. In 2001, he received his doctor’s degree. From 2001 to 2003 he participated in a postdoctoral programme focusing on oncogenesis at the California Pacific Medical Center, U.S.A. In 2005, he was invited as a visiting professor to the Hepatobiliary Surgery Center of Hospital de Hautepierre, Louis Pasteur University (France) for half a year. In 2006, he was promoted to Chief Surgeon and in 2007, he was appointed Director of the department of HPB Surgery in the Beijing Cancer Hospital. In 2008, he became a Professor at Peking University, School of Oncology. From August to September 2008, he was an academic visitor to the Pancreatic Surgery Center of Johns Hopkins Hospital (USA). He currently works as the Deputy Chief of the Department of Surgery in Peking University Cancer Hospital and is the Director of the Department of Hepato-Pancreato-Biliary Surgery. His clinical and research activities focus on diagnosis and treatment of primary and metastatic hepatic carcinoma, cholangiocarcinoma, pancreatic cancer and retroperitoneal tumours. He is the pioneer of some delicate radical surgeries which aim to improve the resection rate of hilar cholangiocarcinoma and pancreatic cancer. He has promoted the new concept of colorectal liver metastases and related techniques, and developed the first multidisciplinary treatment guidelines for colorectal liver metastases in China. He was supported by the National Natural Science Foundation and participated in the pancreatic cancer genome study under the National High-tech R&D Programme. He established the first CME Center of the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO) in China. He is the Beijing Health system Academic Leader in Hepato-Pancreato-Biliary oncological surgery and an Honorary Professor of Cardiff University (UK). He was appointed Deputy Secretary-General of IASGO, Chairman of the Pancreatic Cancer Committee of Chinese Society of Clinical Oncology (CSCO) and the Chinese Strategic Alliance of Technology Innovation in Minimally Invasive Tumour Therapy, and Vice-Chairman of the Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Committee of CSCO. He is also a faculty member of the International School of Surgical Oncology (ISSO), a member of the Fourth CSCO Executive Committee, the Beijing Oncology Society of Chinese Anticancer Association and the Chinese Geriatric Oncology Society. He is on the editorial board of several renowned medical journals at home and abroad.
Session 2a

CLINICAL TRANSLATIONAL - UPPER GASTROINTESTINAL AND HEPATOBILIARY

FB02A03
Cholangiocarionoma – can West meet East?

Mr Malik is a consultant hepatobiliary surgeon and clinical lead for digestive surgery at the University Hospital Aintree. Mr Malik has introduced complex liver surgical techniques within the unit. These include vascular resections and the use of transplant techniques to facilitate liver resections. He has extensive experience having performed in excess of 500 liver resections. In addition, he has an interest in retroperitoneal sarcoma surgery. Mr Malik has also led the development of an active research programme that has links to the University of Liverpool; the Liverpool CRUK Trials Unit; MRC Centre for Drug Safety; Royal Liverpool University Hospital; Clatterbridge and the Christie Oncology Hospitals. He is currently supervising a number of PhD and MD students and has in excess of 70 publications within his field of interest. Mr Malik is also a member of the NCRN Hepatobiliary and Upper Gastrointestinal Subgroup as well as Honorary Secretary to the British Association of Surgical Oncology. In addition he is an active participant in a number of professional associations.

FB02A04
Relative cost per life-year gained of treatments with curative intent for T3NXM0 upper gastrointestinal cancer

Professor Lewis hails from the Gwendraeth Valley in South Wales. After his general education at Ysgol David Hughes in North Wales, he graduated from the Welsh National School of Medicine in 1984. Following basic surgical training rotations in SE Wales, he undertook a period of research, higher surgical training and a lecturer post in surgery at the University of Leeds at The General Infirmary. He was appointed Consultant General Surgeon at the Royal Gwent Hospital Newport in 1995, with an interest in gastrointestinal oncology. He subsequently specialised in Upper GI surgery, and moved his practice to the University Hospital of Wales, Cardiff and Vale University Health Board in 2005, to facilitate the centralisation of UGI cancer services in SE Wales and where he is the clinical lead for UGI Cancer. He has a clinical research pedigree originating from his experience in academic surgery in Leeds, and has authored over 300 scientific publications in the fields of gastrointestinal surgery and postgraduate surgical education. The UGI oncological element of his research has been recognised by the Nishi Memorial Award of the Japanese Gastric Cancer Association in 2003, a Hunterian Professorship by the Royal College of Surgeons of England in 2007, the award of the senior doctoral degree of DSc in 2011, and an honorary professorship by Cardiff University in 2011. He is a member of the SAC in General Surgery, one of the current general surgical RSPAs for Wales and is Head of the Wales Postgraduate School of Surgery and Associate Dean.

FB02A05
CDH1 (cadherin-1) germline mutations in Chinese diffuse gastric cancer

Professor Jia works for the Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing. Her research interests include hereditary gastric cancer and cancer metastasis.
Session 2a
CLINICAL TRANSLATIONAL - UPPER GASTROINTESTINAL AND HEPATOBILIARY

FBO2A06
Surgeon level outcome reporting for upper GI (UGI) cancer operative mortality: A view from over Offa’s Dyke

Mr Blackshaw studied and trained in Cardiff before completing his general surgical training in Wales. He took up a consultant post in August 2009 at the University Hospital of Wales. His research explored factors affecting outcomes in the management of stomach cancer and was awarded a doctorate for this work from Cardiff University. His interests include upper GI cancer resection for oesophageal and gastric cancer, laparoscopic anti-reflux surgery, laparoscopic biliary surgery and all other UGI surgery for both benign and malignant conditions. He is also involved in surgical training, medical education and research.

FBO2A07
The importance of antigenic targets in cancer: Lessons from colorectal cancer

After reading medicine in Cambridge and London, Professor Godkin became a research fellow in the Nuffield Department, Oxford with Professor Adrian Hill and Professor Derek Jewell, working on the immunogenetics of coeliac disease and HLA class II/CD4+ T cell biology. After leaving Oxford he became a lecturer at Imperial College continuing research in Professor Peter Openshaw’s laboratory. He finished his clinical training in GI/Hepatology at St Mary’s with Professor Howard Thomas. Since moving to Cardiff, he has worked increasingly on cancer immunology, focusing on colorectal cancer in humans. He now runs a laboratory in the Henry Wellcome Building, whilst continuing a clinical commitment.

FBO2A08
The FOCUS4 trial group

Dr Adams is a Reader and honorary consultant clinical oncologist at Cardiff University and Velindre Cancer Centre. He is the interim Director of the Wales Cancer Trials Unit. His clinical practice and research is focused on lower gastrointestinal cancers. He is Chair of the National Cancer Research Institute Anorectal Cancer Subgroup, Co-Chair of CTRad early phase trials and is active in national and international research organisations including IRCI the International Rare Cancer Initiative (for anal cancer) and ARCAD. He chairs the Biomarker Development Group for the UK phase III FOCUS4 trial in metastatic colorectal cancer and is Chief Investigator for the FOCUS4 D trial. He leads on the radiotherapy quality assurance programme for the UK ARISTOTLE, COPERNICUS and TREC trials. He oversees collaborative translational research in numerous phase II/III colorectal cancer trials. He was a founder member, and is now Chair of the South Wales Cancer Care Link with Sierra Leone.
Session 2b

CLINICAL TRANSLATIONAL - BREAST AND ENDOCRINE

Co-Chairs

Professor Robert Mansel
CBE FRCS (Eng and Edin)
Professor of Surgery,
School of Medicine,
Cardiff University

Professor Fengxi Su
Head of Department of
Breast Surgery,
Sun Yat-Sen Memorial Hospital,
Sun Yat-Sen University

FBO2B01
Certification of breast units in Europe - a recipe for improved results of cancer treatment

Professor Mansel is Professor of Surgery in the School of Medicine, Cardiff University. His research interests include benign breast disease, sentinel node biopsy, prevention trials, and surgical innovations in breast disease. He is the UK Principal Investigator for the AMAROS trial, and local PI for the IBIS trials. As President of EUSOMA, he is an auditor for the European certification process of breast units. He is on the executive board of the ECCO and the EBCC conferences. He is an invited lecturer worldwide and has been recognised by the Welsh Government and the UK Government for his pioneering work in breast cancer.

FBO2B02
Clinical outcomes of breast-conserving surgery in patients using a modified method for cavity margin assessment

Professor Su is a breast surgeon, and Chief Professor at the Breast Tumour Centre in Sun Yat-Sen Memorial Hospital, Sun Yat-sen University. His research interests include comprehensive management of early-stage breast cancer. He is one of the pioneers to advocate breast-conserving surgery and sentinel lymph node biopsy in China; the breast conservation rate in early-stage breast cancer patients reaches up to 57% in his Centre. Another area of research interest is oncoplastic breast surgery and disease management. His Breast Tumour Centre consists of several divisions, including breast surgery, breast oncology, breast diagnostic and laboratory. He has established the concept of a “one-stop service” in clinic, where patients can receive a physical examination, breast ultrasound and/or mammogram and get the results and advice on the same day. He is in charge of a prospective randomized clinical trial, which is funded by Sun Yat-Sen University. He is also the President of the Society of Breast Cancer, Guangdong Medical Doctor Association and Honorary President of Society of Breast Diseases, Guangdong Medical Association. He has published 36 SCI-indexed articles in peer-review journals such as Annals of Surgical Oncology, Breast Cancer Research and Treatment, Journal of Surgical Research and BMC cancer.
Fighting Cancer Together

Session 2b

CLINICAL TRANSLATIONAL - BREAST AND ENDOCRINE

FB02B03

E-cadherin deficiency associates with poor response to tamoxifen in ER+ invasive ductal breast cancer

Dr Hiscox is currently Senior Lecturer in Cancer Biology within the School of Pharmacy and Pharmaceutical Sciences, Cardiff University. He has a long-standing interest in cancer invasion and metastasis, the subject of his PhD at the School of Medicine in Cardiff, particularly in the context of drug resistance in a range of tumour types. The long term goal of his laboratory is to better understand the cellular and molecular pathways underlying metastasis in order to identify novel therapeutic targets. His research group is actively engaged in three themes of multidisciplinary, cancer-focused research:

- Exploring the role of non-receptor tyrosine kinases as mediators of drug response and resistance and understanding their value as therapeutic targets.
- Investigating the complex interplay within the tumour microenvironment, exploring how tumour cells interact with, and are influenced by, fibroblasts and bone cells and how these interactions can support metastases.
- Identifying molecular determinants of adverse response to targeted therapies and determining their potential for use as predictive biomarkers for cancer patients and therapeutic exploitation.

FB02B04

Surgical management of the axilla in breast cancer following neo-adjuvant chemotherapy

Following medical training at Cardiff Medical School and completion of the All Wales Surgical Specialist Training programme, Ms Davies was appointed as Consultant Breast Surgeon at University Hospital Llandough, Cardiff in 2010. Clinical interests lie in the surgical dilemmas associated with neo-adjuvant chemotherapy, family history and, having trained in oncoplastic breast surgery, ensuring patients are offered the full repertoire of reconstructive options. Academically, interests lie in breast cancer invasion and metastasis and the role of intercellular adhesion in this process, particularly in the context of triple negative and HER2-positive positive breast cancer.
Session 2b
CLINICAL TRANSLATIONAL - BREAST AND ENDOCRINE

**FBO2B05**

*Application of ultrasound-guided vacuum-assisted percutaneous excision technique in non-palpable breast lesions*

After completing an MD at Capital Medical University, Dr Ge began a career as a surgeon at the Department of General Surgery, Beijing Friendship Hospital, affiliated to Capital Medical University. He is now an associate professor of treatment majoring in breast and thyroid diseases. He previously studied with the Metastasis and Angiogenesis Research Group (now CCMRC), Cardiff University School of Medicine, Cardiff, UK in 2010.

**Dr Zhicheng Ge MD**

*Consultant Breast Surgeon, Beijing Friendship Hospital, Capital Medical University*

**FBO2B06**

*3D culture of HER2 over-expressing breast cancer cells promotes AKT to MAPK pathway switching and loss of response to therapy*

Professor Barrett-Lee is the lead role for breast cancer academic clinical research at Velindre NHS Trust and at the Institute of Cancer and Genetics, Cardiff University. The Velindre Cancer Centre provides specialist cancer services to 1.5 million people living in South East Wales. In his own practice based at the Cancer Centre, breast cancer recruitment figures have exceeded the targets set by the Wales Cancer Trials Network (WCTN). On a national level, he is the lead breast oncologist for the SE Wales Network, and Vice-Chair (2007) of the breast cancer NSAG which advises Welsh Government and is a member of its guidelines group. He is also a member of the UK NCRI Breast Group (elected 2004), recently helping to develop and present national guidelines for the monitoring and management of cardiac effects from the use of adjuvant trastuzumab (Herceptin) therapy. In 2009, he was elected Chair of the UK Breast Cancer Intergroup charged by the NCRI. He is a member and secretary of the British Breast Group. In 2006, his breast cancer team at Velindre received a runners-up award in the “Hospital Doctor Awards” for the best UK oncology team of the year. He became Medical Director and Responsible Officer of the Velindre NHS Trust in February 2010; responsible for the Velindre Cancer Centre and The Welsh Blood Service.

**Professor Peter J. Barrett-Lee MBBS BSc MD (Lond) FRCR FRCP (Edin) FRCP (Lond)**

*Medical Director and Consultant Clinical Oncologist, Velindre NHS Trust, Cardiff University*

**FBO2B07**

*Outcome for differentiated thyroid cancer – a single centre experience*

Mr Scott-Coombes is a consultant in endocrine surgery at University Hospital of Wales, Cardiff. He qualified from Westminster Medical School and trained in endocrine surgery at Hammersmith Hospital. He was appointed a consultant at King’s College Hospital in London in 1996. In 2002 he moved to Wales. He is President of the British Association of Endocrine and Thyroid Surgeons and an executive member of the European Society of Endocrine Surgeons. He has published on most aspects of endocrine surgery and written chapters in leading undergraduate and postgraduate textbooks. He is chairman of the board of examiners for the European endocrine examination.

**Mr David Scott-Coombes**

*Consultant Endocrine Surgeon, University Hospital of Wales*
**Session 2c**

**BASIC AND TRANSLATIONAL**

---

**Co-Chairs**

**FBO2C01**

*Myeloid cells in liver metastasis; role of FGF2*

Professor Muschel obtained her MD, PhD degree at Albert Einstein College of Medicine in New York City. She received her clinical training at Cornell and Columbia also in New York City and fellowship training at the NCI, NIH in Bethesda MD. She joined the faculty at the University of Pennsylvania in Philadelphia rising to the rank of Professor, before moving to Oxford University where she is a Professor in the Department of Oncology and Deputy Director of the CRUK/MRC Oxford Institute of Radiation Oncology. Her work has focused upon developing preclinical methods for determination of targets for therapy in metastatic cancer and in radiation therapy.

**Professor Ruth J Muschel**

**MD PhD**

*Professor, University of Oxford*

---

**FBO2C02**

*MAGI3 negatively regulates WNT/B-catenin signalling and suppresses malignant phenotypes of glioma cells*

After completing a PhD at the Chinese Academy of Medical Sciences and Peking Union Medical College, Professor He began his postdoctoral career at Emory University and then became a Professor in the Department of Biochemistry and Molecular Biology in Capital Medical University, Beijing, China. His research interests include investigating the roles of PDZ proteins such as NHERF in regulating expression, stability and signalling of GPCRs such as ßARs, MAS and GPER, together with a continued interest in understanding how PDZ proteins can be modulated to control cancer cell proliferation, invasion and migration. He has a special interest in understanding how NHERF family proteins regulate EGFR, GPER and PTEN assembly and function in cancer. His work has also involved examination of the roles of NHERF in regulating cytoskeleton assembly during invasion and metastasis of cervical carcinoma. Other research interests include investigating how PDZ proteins regulate ßARs signalling in cardiac failure.

**Professor Junqi He**

**PhD**

*Professor in Biochemistry and Molecular Biology, Capital Medical University*
Session 2c
BASIC AND TRANSLATIONAL

FB02C03
Molecular modelling in anticancer drug design: The discovery of the BCL3 inhibitors

Dr Brancale is a senior lecturer in medicinal chemistry at the Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University. He received an undergraduate degree in Chimica e Tecnologia Farmaceutiche from the University of Rome “La Sapienza” in 1996. In 2001 he was awarded a PhD from the Cardiff University for a thesis on a new group of nucleosides with anti-VZV activity. From February 2001 to September 2002 he undertook postdoctoral research in Professor Chris McGuigan’s group, working on an antiviral project sponsored by GSK. As a lecturer, he has focused his research on the computer-aided design and synthesis of novel anticancer and antiviral compounds. He has authored more than 100 peer-reviewed articles and he is an inventor on seven patents. Dr Brancale has been involved in several projects that have moved from basic medicinal chemistry to the clinical evaluation stages. He is currently a member of the Scientific Advisory Board of Synergy Pharmaceuticals and he is one of the Scientific Founders of Tiziana Life Sciences, a LSE listed company interested in developing novel anticancer compounds.

Professor Lu-Gang Yu
Deputy Director, Centre for Glycobiology, University of Liverpool

FB02C04
Circulating galectin-3: Metastasis promoter and therapeutic target

Professor Yu is a Professor of Cancer Glycobiology and Deputy Director of the Liverpool Centre for Glycobiology. He is a member of the British Association for Cancer Research, Biochemical Society and Society of Glycobiology. He currently serves on the editorial boards of a number of international journals in cancer and glycobiology fields. His research interests are in cell glycosylation and carbohydrate-binding proteins (e.g. the galactoside-binding galectins) in cancer progression and metastasis and the development of novel anti-metastasis agents.

Professor Zhenwen Chen
PhD DVM
Head of Department of Biological Sciences, Capital Medical University

FB02C05
Microsatellite instability detected in tumour-related genes in C57BL/6J mice with thymic lymphoma induced by n-methyl-n-nitrosourea

After graduating from China Agricultural University, Professor Chen began to devote himself to teaching and research in the laboratory of Capital Medical University. He has established genetic monitoring system of in vivo models by microsatellite. His work has also involved detecting microsatellite polymorphism of Tg KO natural mutation in vivo and microsatellite mutation. In recent years, he has focused on microsatellite instability mechanism of tumour in in vivo models (induced by ENU, MNU, Cd) and in a number of clinical patients.
FB02C06
Disulfiram – an anti-alcoholism medicine giving cancer patients new hope

Professor Wang obtained his MB from Hebei United University, China and his Msc/MD from the Postgraduate Medical School Hospital, Beijing. He was awarded his PhD from Manchester Metropolitan University, UK. Before joining the University of Wolverhampton in 2005, he worked as a senior research scientist in Paterson and Beatson Institutes for Cancer Research, University of Aberdeen. Professor Wang’s research interests focus on modulation of hypoxia and NFκB and CSC to tackle chemoresistance. He has identified an antialcoholism drug, disulfiram, as a very strong NFκB and CSC inhibitor. In collaboration with China, Europe and USA, his team is using a nano-delivery system to translate disulfiram into cancer therapeutics.

FB02C07
Altering the vasculature to promote tumour immunity

Professor Gallimore gained a DPhil in Professor Andrew McMichael’s laboratory in Oxford, studying the anti-viral role of cytotoxic T cells in SIV infection, subsequently moving to Professor Rolf Zinkernagel’s laboratory to study the correlates of anti-viral immunity. The recent focus of the Gallimore laboratory however has been on the regulation of anti-tumour immune responses. This has resulted in a body of work detailing the impact of regulatory T cells on tumour development in both models and humans. The aim of the group is to take basic research using in vivo models of cancer through to testing novel immunotherapies in cancer patients. Recent findings indicate that Tregs can direct specialized vascular differentiation in tumours resulting in T-cell recruitment and cancer rejection. These studies open doors for novel avenues of immunotherapy.
Session 3a
CLINICAL TRANSLATIONAL - LUNG, HEAD AND NECK

Co-Chairs

Professor Yue Yang PhD
Chief Physician and Director, Department II of Thoracic Surgery, Beijing Cancer Hospital and Institute

Dr Jason Lester
Consultant Clinical Oncologist, Velindre Cancer Centre

FBO3A01
Tumourigenic potential of circulating tumour cells in pulmonary venous blood from non-small cell lung cancer patients in a xenograft model

Professor Yang is the Chief Physician and Director at the Department II of Thoracic Surgery, Peking University School of Oncology, Beijing Cancer Hospital and Institute. He has been in this position for more than 10 years. His current research is divided into two parts. The first part is to perform clinical trial for perioperative period target therapy in the lung adenocarcinoma. The second part is to investigate clinical significance and molecular mechanism for drug resistance in lung cancer. Recently, his research focused on the phenotype of circulating tumour cells in predicting drug resistance and outcome for non-small lung cancer. As a corresponding author, he has published more than 20 papers in journals such as the Cancer Letter, Plos One, JBC and CRCO. He has received funding from the National Natural Science Foundation, National High Technology Research and Development Programme and grants for the key subject of lung cancer.

FBO3A02
EGFR mutation-positive NSCLC: The South Wales experience

Dr Lester is a consultant clinical oncologist at Velindre Cancer Centre, Cardiff and Honorary Research Fellow at the Cardiff School of Medicine. He is the Chief Investigator for both the ISTART trial (dose escalated radiotherapy in lung cancer) and the SKOPOS trial (5T4 vaccine in mesothelioma). His is the Co-Director of Stepping Stones, the Wales-based lung cancer charity which has raised around £1 million to date to support research in the lung cancer field within Wales. He is a member of the Lung Cancer National Service Advisory Group (Wales) and sits on the committee of the British Thoracic Oncology Group. He was appointed Associate Clinical Director at Velindre Cancer Centre in 2012.
Session 3a
CLINICAL TRANSLATIONAL - LUNG, HEAD AND NECK

**FBO3A03**
The combination of a novel bruton tyrosine kinase (BTK) inhibitor PLS123 and mTOR inhibitor everolimus synergistically induces anti-tumour activity in mantle cell lymphoma

Professor Song is the Professor of Medical Oncology and the Vice-Chief of the Lymphoma Department at Peking University Cancer Hospital and Institute. She graduated from Shandong Medical University with a Bachelor Degree in 1993 and with a Master and Doctor Degree of Hematology in 1998. Between 2004-2006, she held a postdoctoral position at the Peking University Health Science Center, China. Between 2009-2010 she was a Visiting Scholar in Nebraska Medical Center, USA. She is currently Vice-Secretary of the Junior Oncologists Association of Lymphoma Society (Anti-cancer Association of China, CACA); Vice-Secretary of Hematology Malignancies Association of Geriatric Oncology Society in China (CGOS) and committee member of Anti-Lymphoma Union of China.

**FBO3A04**
The blood brain barrier and the prevention of metastatic disease

After a PhD in molecular biology at Cardiff University, Dr Martin began a postdoctoral career at The University of Wales College of Medicine, investigating the role of Hepatocyte Growth Factor (HGF) on endothelia and later with its antagonist to cancer research. Other research interests include the interaction of cancer cells in cell-adhesion and cell-signalling and in how the cell adhesion molecule VE-cadherin is involved in angiogenesis. Since 1998, she has been involved in researching the role of tight junctions in cancer (during metastasis) and in endothelia (during angiogenesis). Her award winning research includes investigating how tight junctions can be modulated to control cancer cell dissociation and invasion, together with a continued interest in angiogenic factors and their role in metastasis. She has a special interest in the mechanisms whereby HGF can control tight junction assembly and function in both cancer and endothelia. Currently, she is investigating the role of tight junctions in the control of the blood brain barrier (BBB) during cancer metastasis.

**FBO3A05**
Endoscopic removal of ethmoid osteomas under navigation guidance

Professor Song is Chairman of the Department of Otolaryngology, Head and Neck Surgery of Yantai Yuhuangding Hospital, Qingdao University and was visiting professor of University of Texas MD Aderson Cancer Center from October 2011 to November 2012. His research interests involve clinical and basic research of head and neck cancer and his work also includes nasal skull base surgery and post operative repairing of head and neck surgery. He has published papers in the field of cancer molecular epidemiology, genetic predisposition, gene polymorphisms and on the risk of tumours and clinical prognosis.
Co - Chairs

FBO3B01
Remote-controlled robotic surgery for cancer

Professor Kynaston is Professor of Urological Surgery at Cardiff and Vale University Health Board and Cardiff University. Professor Kynaston qualified in Liverpool Medical School and trained in the North West of England and South Wales. He received specialist training in Australia, Chicago and Leuven specialising in cancer surgery. His main research interests are in prostate cancer and the conduct of phase 2/3 clinical trials both nationally and internationally, particularly in association with the Medical Research Council. Professor Kynaston is currently the Chairman of the Academic Urology Section of the British Association of Urological Surgeons. In the last 12 months he has led the Wales bid to develop robotic cancer surgery with the opening of a state of the art Robotic Cancer Centre in Cardiff.

FBO3B02
A randomized, open-label, multi-center phase II study to compare bevacizumab plus sorafenib versus sorafenib for the third-line treatment of patients with metastatic renal cell carcinoma (NCT02330783)

Professor Guo is the Chief Physician for the Department of Melanoma and Kidney Cancer at the Peking University Cancer Hospital and Institute, as well as the Deputy Director at the Beijing Institute for Cancer Research, both located in Beijing, China. He is also the President of the Asia Melanoma Group, as well as a member of the Global Melanoma Task Force (GMTF). Prior to taking up his position as Chief Physician in 2008, he worked as an Associate Chief Physician and Vice-Professor at Peking University Cancer Hospital for five years. In 2002, he earned his PhD in Immunology from the Second Military Medical University, Shanghai. From 2007 to 2008, he was the President of the Melanoma Forum at the Chinese Society of Clinical Oncology CSCO meetings, and in 2013, won first-class awards for ‘Excellent Research’ at CSCO. He has been published numerous times in both his native Chinese and other languages. Research interests lay in tumour-associated hot spots, including chemokine and chemokine receptors, the development of tumour vaccines, and cancer-targeted therapies.
**Session 3b**

**CLINICAL TRANSLATIONAL - GYNAECOLOGY AND UROLOGY**

**FB03B03**

*Screening for ovarian cancer and the challenges ahead: Results from the multicentre UKCTOCS study*

Professor Amso is a Professor in Obstetrics and Gynaecology at the School of Medicine, Cardiff University and senior consultant in gynaecology. He qualified from the College of Medicine, University of Baghdad, Iraq in 1974, obtained his MRCOG in 1985 and PhD from London University in 1996. He finished his higher clinical training in obstetrics and gynaecology at the Royal Victoria Infirmary, Newcastle upon Tyne (1992-1994) and worked as a consultant at Gateshead Hospitals NHS Trust (1994-1998). Professor Amso undertakes teaching and clinical duties at the University Hospital of Wales where his clinical interests are in reproductive surgery and minimally invasive techniques. He regularly supervises undergraduate and postgraduate (MD/PhD) students and has been the Director of Cardiff University Ultrasound Masters Programme since 2004. Professor Amso has been the local Principal Investigator of the United Kingdom Collaborative Trial for Ovarian Cancer Screening (UKCTOCS) and is a member of its ultrasound subcommittee. He is the Founding President of the British Society for Gynaecological Imaging.

**FB03B04**

*The comparison of bladderscan and ultrasound system on evaluating the bladder capacity*

Professor Fu began a medical physicist career at Chongqing Cancer Hospital and Institute, investigating the quality assurance and quality control in external beam radiotherapy, after completing his PhD at the Shanghai Institute of Applied Physics, Chinese Academy of Sciences. He has proposed a modified conformity index based on extended volume to correct the insensitivity of previous conformity indices to reference dose shape. His work has also involved dosimetric characteristics of different radiation therapy for primary leiomyosarcoma in the spine. Other research includes the angle dependence of dosimetric verification systems and the interaction process between X ray and different matters using the Monte Carlo method.
Session 3b
CLINICAL TRANSLATIONAL - GYNAECOLOGY AND UROLOGY

FBO3B05
*MicroRNA changes in PTen induced prostate intraepithelial neoplasia (pin)*

Dr Dart’s research is focused on prostate cancer, and the mechanisms of disease progression and resistance to hormonal therapy. He is studying the mechanisms of androgen receptor signalling both in developmental biology and in prostate cancer with an aim to discover mechanisms of androgen independence. A second avenue of research includes the study of microRNAs in the development of prostate cancer and in the transition from normal to malignant and invasive tissue. Of additional interest is the possibility of using microRNAs as both potential therapies in their own right, and as potential biomarkers of prostate cancer disease and progression, especially for clinical decision making.

Dr Dafydd A. Dart
Research Fellow, CCMRC, Cardiff University

FBO3B06
*Management of peritoneal metastases in epithelial ovarian, fallopian tube and primary peritoneal carcinoma*

Professor Gao is Chief and Associate Professor of the Department of Gynaecologic Oncology. She received her Bachelor of Medicine from Peking University Medical College in 1986 and her Master of Obstetrics and Gynaecology in 2000 from Peking University Health Science Centre. She has previously undertaken residency in Peking University First Hospital, Tsan Yuk Hospital, Hongkong University and was attending surgeon in Peking University First Hospital. Memberships include: Chinese Medical Association of Gynaecologic Oncology Society, Chinese Anti-Cancer Association, Committee of Gynaecological Oncology, Chinese Medical Association of Gerontology and the Society of Gynaecologic Oncologists of America.

Professor Yunong Gao MM
Chief, Department of Gynaecologic Oncology, Peking University Cancer Hospital and Institute
Session 3c
BASIC AND TRANSLATIONAL

Co-Chairs

Professor Karl Matter
Professor of Cell Biology, Department of Cell Biology, Institute of Ophthalmology, University College London

FB03C01
The tumour suppressor DLC2 ensures mitotic fidelity by coordinating spindle positioning and cell-cell adhesion

Professor Matter received his PhD in Biochemistry from the University of Basel, Switzerland, in 1989. After a postdoctoral fellowship at Yale University, USA, he returned to Switzerland where he started his independent research programme at the University of Geneva, supported by the Swiss National Science Foundation. In 2001, he moved to London and is now a Professor of Cell Biology at the UCL Institute of Ophthalmology. The research of his laboratory focuses on the structure and function of epithelial cell-cell junctions, and the molecular mechanisms that guide epithelial cell polarisation and differentiation in health and disease.

FB03C02
C-KIT overexpression promotes development of colorectal mucinous adenocarcinoma in murine model

After a PhD at Medical College, Ehim University, Professor Zhou began a postdoctoral career in Biology at Waseda University, investigating the role of C-KIT in gastrointestinal interstitial cells of Cajal. He is currently Professor in Histology and Embryology at Capital Medical University. His current research focus is on searching for the involvement of C-KIT/SCF in tumourigenesis, proliferation and invasion of colorectal cancer, together with an interest in how microRNAs modulate C-KIT/SCF to control colorectal cancer cell growth and invasion. His research interests also include the potential therapeutic application of natural polyphenol compound (e.g., Resveratrol) for colorectal cancer. He has a special interest in the role of gastrointestinal microbes in tumourigenesis of colorectal cancer.

Professor Deshan Zhou
PhD
Head of Department of Anatomy, Capital Medical University
Session 3c
BASIC AND TRANSLATIONAL

FB03C03
WNT-11 and JNK pathway: The two faces of neuroendocrine-like differentiation in prostate cancer

Dr Uysal-Onganer finished her PhD by completing her studies both at the Centre for Hepatology in UCL and the Medical School of Marmara University in Turkey. She has been working at Imperial College London since 2003. Her research experience involves a range of cell signalling mechanisms, and the functional and molecular aspects of cancer. She studied on voltage-gated sodium channel (VGSC) expression in metastatic disease at Prof Djamgoz’s laboratory and was first to demonstrate functional upregulation of VGSCs in human small-cell lung cancer, in vitro and in vivo. The results further revealed the ‘neuronal’ characteristics of strongly metastatic carcinoma cells, which were reviewed, in a clinical context, in British Journal of Cancer. She collaborated with Baroness Greenfield and demonstrated that an acetylcholinesterase-derived peptide has significant effects on metastatic behaviour of human breast cancer cell lines. She has been working on WNT signalling and prostate cancer since 2006. She was awarded a Certificate of Medical Biology Education and Learning (level achieved – Reader) from the Higher Education Authority of Turkey and has been working as a cell and molecular biology senior lecturer at University of Bedfordshire since 2012. She is an honorary lecturer at Imperial College London and teaches the annual Cancer Biology Course. She has also been actively involved in fund-raising activities with charities such as the Prostate Cancer Research Fund (PCRF) and the Prostate Cancer Charity (PCC).

FB03C04
The role of NHERF in breast cancer

After a PhD in Molecular Biology at Peking University Health Science Center and postdoctoral training at Tsinghua University, Professor Zheng began a research career at Capital Medical University, investigating the role of NHERF family on tumour. Her research interests include investigating how behaviour can be modulated tumour by NHERF family and its underlying molecular mechanism. Her work has also involved the examination of NHERF family expression in cancer, how their expression levels are regulated and how these regulatory factors influence tumour behavior. She is currently Associate Professor in the Department of Biochemistry and Molecular Biology at Capital Medical University.
FB03C05
Physicochemical characterisation of bisphosphonates and their potential application for cancer metastasis in bone

Dr Xia is a senior lecturer in Regenerative Medicine at Swansea University. He obtained a DPhil in Oxford University in 2005 and worked in a postdoctoral position, and then as a senior research fellow in Oxford before he moved to Swansea in 2010. He qualified in medicine in China and worked as an Associate Professor in Orthopaedic Surgery at the Union Hospital Affiliated to Tongji Medical University before he came to the UK in 1998. Dr Xia’s research interest is mainly in the field of bone biology and skeletal tissue regeneration, including the development of mesenchymal stem cell/bone tissue engineering 3D culture system, the application of anabolic/anti-catablic reagent for bone regeneration, and recently 3D in vitro models for cancer related research.

FB03C06
ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis and barrier formation

Professor Balda did her PhD in Physiology at the Centre for Research and Advanced Studies, Mexico and postdoctoral studies at Yale University, U.S.A and the University of Geneva, Switzerland. In 2001, she started at the UCL Institute of Ophthalmology first as a lecturer and, since 2011, as a Professor of Cell Biology. Her passion is to understand how epithelial and endothelial cells form selective barriers between compartments of different composition. Thus, her research interest is to disclose the molecular mechanisms of how intercellular junctional complexes are regulated during physiological and pathological conditions as well as their crosstalk with signalling pathways triggered by cell-extracellular matrix interactions.
Session 4a  
**CLINICAL TRANSLATIONAL – GASTROINTESTINAL**

### Co-Chairs

**SBO4A01**  
*The dual PI3K/mTOR inhibitor BEZ235 exerts prominent antitumour activity in HER2 positive gastric cancer and has synergy with Trastuzuma B*

Professor Shen is Professor at the Department of GI Oncology, and Vice-President of Peking University Cancer Hospital and Institute. She received her oncology degree from Peking Medical University and specialised in gastrointestinal cancers. Her interests include the individual treatment for advanced gastric cancer and colorectal cancer with liver metastases, targeted therapy for gastrointestinal stromal tumour, chemotherapy and multidisciplinary treatment for the gastrointestinal malignancies and clinical research especially in early stage trials. She participates in global clinical trials and acts as PI for many domestic multicenter clinical trials. Publications include over 100 papers in the last five years as first or corresponding author; 55 SCI indexed, total impact factor of about 150. Memberships include the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO) and Chinese Society of Clinical Oncology (CSCO). She is Chairman of Experts Committee of GIST-CSCO, an executive member of Chinese Geriatric Oncology Society (CGOS) and Colorectal Cancer Committee of Chinese Anti-Cancer Association (CACA), General Secretary of Stomach Committee, a panel member of Gastric and Colorectal Cancer of NCCN (Chinese Version), Deputy Editor-in-Chief for Chinese Journal of the Frontiers of Medical Science (Electronic Version) and Chemotherapy for Gastrointestinal Tumours, an editorial board member for the Chinese Journal of Gastrointestinal Surgery, Chinese Journal of Pharmacovigilance and Global Oncology Express, Chinese J Cancer Research, Cancer Research and Clinic, Journal of Digestive Oncology and Chinese Journal of Clinical Oncology.

**SBO4A02**  
*Modulating the stem cell niche and neoplasia in the murine intestine: Characterising the roles of the WNT and PI3-KINASE pathways.*

Professor Clarke completed his PhD in the laboratory of Sir Martin Evans in Cambridge in 1988, and following that worked with Martin Hooper and Andrew Wyllie as a Royal Society University research fellow in Edinburgh, before moving to become Professor of Genetics in Cardiff, UK in 2000. His research is focused on the generation of novel in vivo models of colorectal, breast and prostate cancer, with a view to using these to understand both basic mechanisms of carcinogenesis and to use them to speed the translational pipeline into the clinic. He is currently Head of Research at the School of Biosciences in Cardiff University, Director of the Cardiff Cancer Research -UK Cancer Centre and also Director of the European Cancer Stem Cell Research Institute. Professor Clarke has recently been Scientific Chairman of the Association for International Cancer Research (AICR) and Deputy Chair of the UK Medical Research Council’s MCMB Board. He is currently a member of the MRC’s Regenerative Medicine Board and also section editor of the journal, Carcinogenesis.
Session 4a
CLINICAL TRANSLATIONAL – GASTROINTESTINAL

SBO4A03
Comparisons of stress and humoral immunologic responses early after laparoscopy-assisted distal gastrectomy performed as a component of fast track surgery for gastric cancer

Dr. Lixin Jiang is Dean of the Department of Surgery, supervisor of postgraduate of Yantai Yuhuangding Hospital and the Medical College of Qingdao University. He has been engaged in the clinical, research and teaching work of general surgery for 20 years, accumulating abundant clinical experience. Remarkable achievements include dealing with digestive tumors, thyroid carcinomas, hernia and abdominal disease. At present, he takes charge of multiple scientific projects including covering IONM in thyroid surgery, cyclophilin D hepatoma cell growth promoting molecular mechanism, FTS in gastric cancer, PIN-1’s function in colorectal cancer cell mitosis and E-cadherin in colorectal cancer lymph node.

SBO4A04
Pulmonary metastasectomy for colorectal cancer: Are we doing the right thing?

Mrs. Eveline Internullo has worked as a consultant thoracic surgeon first in Italy (Parma, Genoa), then in UK (Nottingham, Bristol). She’s currently working at the Bristol Royal Infirmary. In 2006, she was involved with lung metastasectomy research and became a member of the ESTS (European Society of Thoracic Surgeons) Lung Metastasectomy Working Group, on whose behalf she ran a survey on the variability of practice amongst European thoracic surgeons. She subsequently got an MD in Methodology of Research in Italy. She has kept developing her interest for metastasectomy and cooperated on a few research projects with Professor T. Treasure, who is the CI of the ongoing PulMiCC trial, the first international CRT trial on lung metastasectomy for colorectal cancer. Other interests include oesophageal surgery and minimally invasive thoracic surgery.

SBO4A05
Cyclophilin J is a novel peptidyl-prolyl isomerase and target for repressing the growth of hepatocellular carcinoma

Professor Chen graduated from Fudan University. He got his PhD degree in genetics in 2005 and began a postdoctoral career at the Northwestern University. He participated in the research of “The molecular mechanism of tumourigenesis and metastasis of hepatic carcinoma, the diagnosis and treatment” during his Master and PhD studies in Professor Long Yu’s group. During postdoctoral work in Northwestern University, he focused on studying the “Mechanisms of tumour metastasis signal transduction and microRNA silencing” which was funded by the NIH Director’s Transformative R01 Grant in the US. He was the Principal Investigator of “Molecular mechanism study of promoting hepatic carcinoma growth by the novel peptidyl-prolyl isomerase Cyclophilin J” funded by NSFC as well as the grant “Molecular mechanism study of a novel discovery of Pyk2 promoting hepatic carcinoma cell metastasis: binding and phosphorylating E-cadherin?” funded by NSFC. He has published several papers in British Journal of Cancer, GENE, BBRC. He now works as a clinical doctor in the Department of Medical Oncology, Yantai Yuhuangding Hospital.
Session 4b
CLINICAL TRANSLATIONAL – BREAST AND GYNAECOLOGY

Co-Chairs

SBO4B01
Association between BRCA1 and BRCA2 mutations and response to neoadjuvant chemotherapy in women with breast cancer

Professor Xie received his medical degree in 1986 from the School of Medicine, Wuhan University, China. As a resident, he then trained in general surgery. In 1992, he was appointed Specialist of Oncology, working at Zhongnan Hospital, Wuhan University. From 1998 to 2003, he studied and worked as a senior researcher at Cancer Center Karolinska, Karolinska Institute, Sweden where he focused on the function analysis of SYT-SSX fusion gene and obtained his PhD in 2002. In April 2003, he moved to Peking University Cancer Hospital, as Chief of the Breast Cancer Research Laboratory. As a tumour surgeon, he routinely performs operations for breast cancer patients. He also carries out breast cancer research, focusing mainly on translational. His research interests include: the prognostic or predictive markers that sort out the patients who may have a high risk of relapse, or discriminate the patients who may respond to certain types of neoadjuvant chemotherapy regimens and germline mutations in BRCA1/2 or other susceptibility genes in Chinese women with early-onset or familial breast cancer. Professor Xie has published more than 30 peer-reviewed papers in leading oncology journals, such as J Clin Oncol, JNCI, Cancer Res, Oncogene, and Clin Cancer Res and has obtained several key research grants for breast cancer from the Chinese Government.

Professor Yuntao Xie
MD PhD
Chief of Breast Cancer Research Laboratory, Peking University Cancer Hospital and Institute

SBO4B02
Bone morphogenetic proteins in triple negative breast cancer and potential link with epidermal growth factor

After graduating from the Shandong University of Traditional Chinese Medicine with an MB and BCh in 1993, Dr Ye started his clinical training and work at the Department of Surgery in the University Hospital, Jinan, China. He had been a surgeon and clinical teacher before he moved to Cardiff to pursue a PhD in cancer biology in 2004. Following his PhD study of bone morphogenetic proteins (BMP) and their signalling in prostate cancer, Dr Ye continues to explore the mechanism(s) of bone metastasis from prostate cancer and breast cancer, seeking and developing therapeutic approaches particularly by targeting BMPs signalling.

Dr Lin Ye
Lecturer, CCMRC, Cardiff University

SBO4B03
Anti-metastatic and cytotoxic properties of frankincense and scented myrrh

In 1987, Dr Ali completed his degree in applied chemistry at Liverpool Polytechnic (now John Moores University). Over the next 13 years he worked as a both a pharmaceutical chemist (formulation and analytical) in both England and Wales. In 2000, he commenced an academic research position at Cardiff University researching the phytochemistry, molluscidal and mollusc repellent activity of Nigerian and Somali plants. This research led to the filing of three patent applications involving the novel use of myrrh and opoponax (Commiphora spp.) oleoresins as mollusc repellents, anticancer agents and anti-fouling agents. Shortly after this he became the Research Director for a Welsh SME company called the Compton Group; still based at Cardiff University. In 2006, he commenced new research collaborations with Dr Emma Blain and Professor Vic Duance (Cardiff University) studying the anti-inflammatory properties of Somali frankincense. In the same year, he commenced new research collaborations with Professor James Newbold and Dr Kenton Hart (Abeyystwyth University) looking at the antibacterial properties of sandalwood oil in ruminants. Both of these collaborations led to the successful granting of international patents and the awarding of numerous academic grants. The frankincense anti-inflammatory agent is currently undergoing scale-up and clinical trials in the USA. A nutraceutical product based on Somali frankincense is expected to be launched commercially in the USA market at the end of 2015.

Dr Ahmed Y. Ali PhD
Research Director, Compton Group, Cardiff University
Session 4b

CLINICAL TRANSLATIONAL – BREAST AND GYNAECOLOGY

SBO4B04

*Down-regulation of klotho beta is related to breast cancer progression*

Professor Dai has been engaged in clinical diagnosis of surgical pathology and experimental pathology since 1982 and has been teaching for more than 20 years. Her major research focus is on gastrointestinal pathology and hepatopathology. She has taken charge of fifteen provincial research projects and has been awarded eight prizes for Progress in Science and Technology and has published more than ninety academic papers. Additionally, she has held many administrative positions which include, Vice-President of Outstanding People Training Base in Capital Medical University, Executive Director of Clinical Pathology Centre, Director of Pathology and is also a member of the Judicial Expertise Committee for Medical Incidents and the Chinese Pathologist Association.

Professor Jie Dai
Professor of Pathology, Capital Medical University

SBO4B05

*Osteoprotegrin (OPG) receptor activator of nuclear-kB (RANK) and rank ligand (RANKL): A complex interplay between breast cancer progression and the bone*

Dr Owen completed her first degree in Medical Pharmacology in 2011. Upon graduation she undertook a PhD with the Metastasis and Angiogenesis Research Group (MARG) investigating key bone turnover molecules and the role they play in bone metastases associated with osteotropic breast and prostate cancers. During her first postdoctoral research position, as a member of the Cardiff-China Medical Research Collaborative (CCMRC) she is continuing to investigate prostate cancer aetiology with the hope of identifying a new therapeutic target.

Dr Sioned Owen
Research Associate, CCMRC, Cardiff University

SBO4B06

*BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10*

Professor Gong is an Associate Professor at the Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. She started her clinical practice and research career on breast cancer in SunYat-Sen University in 2001. She was appointed as an attending surgeon in the Breast Tumour Centre of Sun-Yat-Sen Memorial Hospital in 2006. She has been involved in preclinical translational studies on medical application of noncoding RNAs in breast cancer since 2007. Her research focuses on the mechanisms of chemo-resistance, biological treatment-resistance and metastasis of breast cancer.

Professor Chang Gong
MD PhD
Associate Professor and Breast Surgeon, Breast Tumour Centre, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Session 4c
BASIC AND TRANSLATIONAL

Co-Chairs

Professor Christopher McGuigan
Professor of Medicinal Chemistry, Cardiff University

Professor Dajen Deng MD
Director for the Division of Cancer Etiology, Peking University Cancer Hospital and Institute

SBO4C01
Protides as a new anti-cancer drug family

Professor McGuigan has 25 years’ experience in drug discovery and development with three new chemical entities progressing from his laboratory to clinical trials in man. He is an expert in nucleosides, that dominate current antiviral drugs and make a significant contribution to anti-cancer treatment. He also chairs the Life Sciences Hub at Cardiff Bay which opened during July 2014 and is the heart beat of life science business growth in Wales. He also chairs the National Research Network in Health and Life Sciences, a £15M initiative aimed at funding 100 new drug discovery projects across Wales. He is also a member of the board of the £100M Arthurian Life Sciences fund.

SBO4C02
P16 methylation is a useful predictor for cancer development from oral epithelial dysplasia in a multicentre prospective study

Professor Deng is Director for the Division of Cancer Etiology and Vice-Director for the Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, PRC) at Peking University Cancer Hospital and Institute. His current research interests include: epigenetic carcinogenesis; malignant transformation, epithelial dysplasia, ncRNA; nucleosome and initiation/extension of DNA methylation; subtyping of carcinomas in the digestive ducts by DNA methylation markers and gene-specific reactivation of silenced genes by artificial transcription factors.
Session 4c

BASIC AND TRANSLATIONAL

**SBO4C03**
*New targets for clinical evaluation in glioblastoma multiforme, a tumour with limited therapeutic options*

Professor Darling is Dean of Research and Head of the University Research Policy Unit at the University of Wolverhampton where he is responsible for the University research policy, governance and supporting postgraduate research education. He directs the Research Institute in Healthcare Science and co-directs (with Dr Tracy Warr) the Brain Tumour Research Centre. He was a founder member and a former secretary and president of the British Neuro-oncology Society. He was a founder member of Brain Tumour North West, a strategic alliance of brain tumour researchers and clinicians across the North West of England. He has been engaged in brain tumour research since 1978 when he worked with Professor David GT Thomas in the Gough-Cooper Department of Neurological Surgery at the Institute of Neurology, National Hospital for Neurology and Neurosurgery in Queen Square, London. His research interests are centred on why malignant brain tumours develop and why they are so often resistant to treatment.

**SBO4C04**
*Discovery of a regulatory motif of human satellite DNA transcription responsive to BATF2/SARI over-expression*

Professor Ding graduated from Beijing Medical University in 1991 with a Bachelor of Medicine. He obtained his PhD degree at the University of Iowa, USA in 2005 majoring in anatomy and cell biology. He joined Capital Medical University in 2006 as a Professor in the Department of Biochemistry and Molecular Biology and was appointed as Department Chair in 2015. His research interests include cancer genetics and gene therapy.
Session 5a
CLINICAL TRANSLATIONAL – GASTROINTESTINAL

Co-Chairs

Professor Xiangqian Su
Vice-President, Peking University Cancer Hospital and Institute

Ms Rachel Hargest
Senior Clinical Lecturer, Cardiff University and Consultant Colorectal Surgeon, University Hospital of Wales

SB05A01
The development of laproscopic colorectomy in China

Professor Su is the Vice-President of Peking University Cancer Hospital (Beijing Cancer Hospital) and the Director of the Department of Minimally Invasive Gastrointestinal Surgery. He graduated from Inner Mongolia Medical College in 1984, and then served as surgical resident and attending surgeon in general surgery. He obtained his Master’s Degree of Surgical Oncology in 1999 at Peking University School of Medicine, and then worked as an attending surgeon at Peking University Cancer Hospital. From 2007 to 2008, he worked as a research associate at the University of California, Los Angeles. In 2009, he established the Department of Minimal Invasive Surgery at Peking University Cancer Hospital. Clinical research interests include focusing on the safety assessment and long-term prognosis analysis of progressive gastric cancer patients treated with laparoscopic radical surgery, and the construction of nomogram-prognostic model for gastric cancer. The projects have been supported by grants from the Beijing Hospital Authority Clinical Technology Innovation Project, Clinical Characteristics and Application Research and the Capital Medical Development and Research Foundation. For basic biomedical research, ongoing projects include biomarker discovery of gastric cancer and colorectal cancer, unravelling the miRNA-cerNA networks in colorectal cancer, and investigating the heterogeneity of colorectal cancer stem cells by single cell sequencing. These projects are supported by the National Natural Science Foundation of China and Peking University (PKU) 985 Special Funding for Collaborative Research with PKU Hospitals.

SB05A02
Risk factors for AIN III and progression to anal cancer in South Wales

Ms Hargest was born and brought up in Cardiff but moved to London as a student. She qualified from Charing Cross and Westminster Medical School, and trained in London, Johannesburg and Toronto and returned to Wales as a consultant surgeon. Her interests include colorectal cancer genetics, polyposis syndromes and intestinal failure. As well as working as a GMC appeals assessor she is also a trustee of the British Association of Surgical Oncology and the Royal Society of Medicine.
Session 5a
CLINICAL TRANSLATIONAL – GASTROINTESTINAL

**SB05A03**
Biomarkers in colorectal cancer
Mr Yiu trained in medicine at University College London with an intercalated BSc in neuroanatomy. While a lecturer in surgery at UCL, he undertook research into the application of monoclonal antibodies in the management of colorectal cancer at the Ludwig Institute for Cancer Research, Royal Marsden Hospital, Sutton. He completed his surgical training at Middlesex and University College Hospitals. He undertook research into MSI in colorectal cancer as a senior lecturer in surgery at UCL. He is now a consultant surgeon at Queen Elizabeth Hospital, London and an honorary senior lecturer at KCL Medical School.

**SB05A04**
Cytoreductive surgery in the management of peritoneal malignancy from colorectal carcinoma
Mr Davies was born and raised in West Wales and attended medical school in Cardiff and graduated from the University of Wales College of Medicine, Cardiff in 1997. He undertook basic surgical training in the South of England and returned to South Wales to complete his higher surgical training. He has undertaken fellowships in Swansea and Basingstoke in advanced pelvic oncology and the management of peritoneal malignancy (Cytoreductive Surgery and HIPEC) respectively. He studied for his doctorate at the Metastasis and Angiogenesis Research Group, Cardiff University (now CCMRC) and wrote his thesis on lymphangiogenesis in colorectal carcinoma. He has also a wide exposure to trauma surgery. He currently works at the University Hospital of Wales, Cardiff as a consultant in general and colorectal surgery, is the departmental lead for trauma and the surgical tutor in emergency general surgery.

**SB05A05**
The key role of HBV mutations in carcinogenesis
Dr Chen is Director of the Beijing Institute of Hepatology and Director of the AIDS Research Centre at You An Hospital in Beijing, China. He is also on a committee of experts for the Chinese National Natural Science Foundation. Previously, he participated in research at the Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon. His current research focuses on hepatocellular carcinoma (HCC) early biomarker screening within a chronic hepatic cohort studied through the Beijing You An Hospital. In five years it is estimated that approximately 20 percent to 30 percent of patients in this cohort will progress from chronic hepatic disease to HCC. Dr Chen and his research team welcome those interested in collaboration.
Session 5a  
CLINICAL TRANSLATIONAL – GASTROINTESTINAL

**SB05A06**  
**FBXW7 orchestrates a failsafe programme against colorectal cancer progression**

After years comprehensive biomedical training (breast cancer oriented) at the Advanced Medical Research Institute of Canada, Dr Li developed his fascination for phosphorylation of AKT and their substrates in an attempt for targeted drug screening. In 2008, he was selected as a Cancer Research UK-funded PhD student (2008-2012) at the Cancer Genetics and Stem Cell Research Group at the University of Nottingham, where he continued as a junior postdoctoral researcher until 2013. While at Nottingham, he utilised genetically modified *in vivo* models to study E3 ligase ubiquitination system, coupled with Wnt and Notch signalling, in colon cancer. In mid-2013, he became a research fellow at UCL and is currently focusing on the genetic and epigenetic consequence of IDH1 mutation in glioblastoma.

*Dr Ningning Li PhD*  
Research Fellow, University College London

---

**Professor Zhongtao Zhang**  
MD PhD  
Director of General Surgery, Beijing Friendship Hospital, Capital Medical University

Professor Zhang is the Director of the General Surgery Department, Beijing Friendship Hospital, and the Director of General Surgery at Capital Medical University, Beijing, China. He is a famous GI surgeon in China and performs hundreds of gastrointestinal laparoscopic operations each year. He is a long-standing committee member and Secretary General of the Chinese Surgical Association, a fellow of the Chinese Association of Surgeons, and Vice-Chief Editor of the Chinese Medical Journal. In recognition of his outstanding work in surgical practice, he has received honours from a number of international surgical associations, such as the American College of Surgeons, the Endoscopic and Laparoscopic Surgeons of Asia and the International Gastric Cancer Association.
Session 5b

CLINICAL TRANSLATIONAL – LUNG AND THE SECOND ‘CHINA – UK LUNG CANCER SYMPOSIUM’

Chair

SBO5B01
A study for early NSCLC resection operation choice

Professor Zhi attended Capital Medical University (CMU) in 1978. After graduating, he worked at the Beijing Chest Hospital in thoracic surgery for 20 years. In April 2003, he went to Xuanwu Hospital, CMU, as Director of Thoracic Surgery and established the Lung Cancer Center, serving as a Director. His research focus for more than thirty years includes lung cancer surgery, multi-disciplinary comprehensive treatment and clinical research. He is famous in China for research successes such as, lung cancer early detection and minimally invasive surgery for individualised treatment of lung cancer. He is the founder of the Thoracic Surgeon Association of Beijing, and also served as Director. He has served as; Executive Vice-President and Director General of the Chinese Medical Doctor Association of Thoracic Surgery; leader of the Thoracic Society for Cardiovascular Surgery Lung Cancer Group of the Chinese Medical Association and the China Association of Hospital Medical Technology Application Management Committee; Director of the Chinese Cancer Foundation Smoking and Lung Cancer Prevention and Control Office; leader of the Primary Lung Cancer Diagnosis and Treatment Clinical Pathway Audit Expert Committee and Director of the Committee of Experts of Thoracic Surgeons. He serves as editor for academic journals including; The Chinese Medical Frontier, Chinese Journal of Cardiovascular Surgery Clinical Thoracic, Cancer Research and Clinical, The Chinese Chest Surgery, Tuberculosis and Lung Disease and Annals of Thoracic Surgery (Chinese version). He is also deputy editor of the Chinese Journal of Lung Cancer, Chinese Journal of Thoracic Cardiovascular Surgery, Thoracic Cancer and the Chinese Journal of Cancer Research and Journal of Thoracic diseases.

Co-Chairs

SBO5B02
Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIS in lung squamous cell carcinoma patients with EGFR mutations

Professor Wang is Chief of Department of Thoracic Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute. Professor Wang obtained a bachelor of medicine in 1987. She went on to major in oncologic pathology in 1994 as master of internal medicine in 1997 as PhD. She completed her postdoctoral study in 1999. She studied at M.D. Anderson Cancer Center in USA as a visiting professor during 2002-2004. Professor Wang is member of the American Society of Clinical Oncology (ASCO), Chinese Anti-Cancer Association (CACA) and Chinese Medical Association. She is on the executive committee of Chinese Society of Clinical Oncology (CSCO), and the standing committee of the CACA Lung Cancer Profession Committee and is the Vice –Chairman of Small Cell Lung Cancer Expert Committee. Professor Wang has acquired sponsorships from National Natural Science Foundation, National 863 Supporting Programme and the Capital Development Research Foundation. In 2010, she received a grant from the China National Funds for ‘Distinguished Young Scientists’ and the ‘Award of Chinese Young Female Scientists.’
Session 5b
CLINICAL TRANSLATIONAL – LUNG AND THE SECOND ‘CHINA – UK LUNG CANCER SYMPOSIUM’

Co-Chairs

**SBO5B03**
*Circulating progenitor cells in lung and other cancers*

Dr Cui is interested in the interaction of tumour cells with the adjacent components including endothelial progenitor cells and osteocyte cells within tumour-associated microenvironment. He is also working on the signalling pathways of MDM2, PSMA and EPH receptors during tumour angiogenesis and metastasis. In addition, he is developing miRNA and CRISPR-based genome editing therapeutics to disrupt tumour outgrowth after delivery with novel self-assembled surfactant-like nanoparticles.

**SBO5B05**
*Lung metastasis: Emerging targets and opportunities for therapeutic intervention*

Biography available on page 34

Dr Stephen Hiscox PhD
FHEA
School of Pharmacy and Pharmaceutical Sciences, Cardiff University

Dr Yuxin Cui
Research Fellow, CCMRC, Cardiff University
Session 5b
CLINICAL TRANSLATIONAL – LUNG AND THE SECOND ‘CHINA – UK LUNG CANCER SYMPOSIUM’

**Professor Songlei Ou MD**
Chief of Department of Thoracic Surgery, Beijing Anzhen Hospital, Capital Medical University

**SB05804**
The long-term result following lung resection combined with off-pump coronary artery bypasses grafting

Professor Ou is a thoracic surgeon who has almost thirty years experience of clinical practice. He is Chief of Department of thoracic surgery and Deputy Chief of the Lung Cancer Center of Capital Medical University. His work focuses on thoracic diseases and their surgical treatments, especially in lung cancer.

**Professor Yanjun Zhu MD**
Chief Physician, Department of Thoracic Surgery, PLA Airforce General Hospital, China

**SB05806**
HSA-MIR-182 downregulates rasa1 and suppresses lung squamous cell carcinoma cell proliferation

Professor Zhu is currently the Director of the Lung Cancer Centre and Thoracic Surgery Department in PLA Air Force General Hospital. After a PhD in Military Medical Institute of Basic Medical Sciences, he began his clinical work as a thoracic surgeon. He has completed thoracic surgery in more than 2000 cases, especially in lung cancer, oesophageal and cardiac cancer. His research interests include investigating the function of mir-182 in NSCLC. He confirmed that mir-182 could downregulate RASA1 and suppress lung squamous cell carcinoma cell proliferation.
Session 5b
CLINICAL TRANSLATIONAL – LUNG AND THE SECOND ‘CHINA – UK LUNG CANCER SYMPOSIUM’

SB05B07
Cancer stem cells (CSC) metabolism and hypoxia as a novel target for treatment of thoracic malignancies

Professor Mutti obtained his MD in 1982, CCT in Respiratory Medicine in 1988, in Oncology in 1993 and his PhD in Oncology in 1994. Since 1999 to 2014, he has been Head of the Department of Medicine and the laboratory of oncology at Vercelli GH in Italy. Since October 2014, he has been Chair of Cancer Research and honorary consultant at the Royal Salford University Hospital, Chairman of GIme, Italian director of IMIG, expert leader of ERS, and a member of the SAB of MARF. His main research focus and achievements include the role of immune response, cell signalling transduction and microenvironment in mesothelioma, with the aim to design novel translational therapies for this tumour.

SB05B08
Combined laparoscopic and thoracoscopic versus open Ivor Lewis oesophagectomy for oesophageal cancer: A retrospective cohort study

Dr Li is Chief Surgeon, doctoral supervisor and Director of the Department of Thoracic Surgery at Chao-Yang Hospital, Capital Medical University (CMU), Beijing. After graduating from CMU in 1984, he completed his residency training at Beijing Chao-Yang Hospital. In 1992, he received his MD from the Department of Surgery, Trinity College, University of Dublin. He then pursued further training on video-assisted thoracoscopic surgery at the Prince of Wales Hospital, the Chinese University of Hong Kong. Dr Li served as the Chief of the Division of Thoracic Surgery at the General Hospital of the PLA Navy, and Professor of the Second and the Third Military Medical Universities of PLA. He is currently the Chair of the Department of Thoracic Surgery, Beijing Chao-Yang Hospital. Dr Li is an international member of STS, member of IASLC, senior fellow of the Chinese Medical Association of Cardiovascular and Thoracic Surgery and vice-chairman of the Beijing Association of Thoracic Surgery. Dr Li now serves on the editorial board of several medical journals including, Thoracic Diseases, Chinese Journal of Cardiovascular and Thoracic Surgery, and the China Journal of Lung Cancer. Over the past five years, he has published more than 40 papers in both Chinese and international medical journals and his research has focused on minimally invasive oesophagectomy.
**Session 5c**

**BASIC AND TRANSLATIONAL**

**Co - Chairs**

**SB05C01**

*Complement, inflammation and cancer – a double-edged sword?*

Professor Morgan graduated in medicine from Cardiff and completed a PhD prior to a two-year stay in the US where he developed his interest in the complement system. He returned to the UK where, generously supported by the Wellcome Trust, he built a large research group working on the complement system, its regulation and roles in disease. His current research focuses on roles of complement and other inflammatory pathways in disease with a particular focus on neurological disease.

**Professor B. Paul Morgan**  
MB PhD FRCPath  
Professor of Immunology,  
Cardiff University

---

**SB05C02**

*Decreased hepatic stimulator substance (HSS) expression promotes hepatocellular carcinoma metastasis via ERK activation*

Professor An is a Professor of Cell Biology at Capital Medical University. Currently he is chairing the Department and the Beijing Municipal Key Laboratory for Liver Protection and Regulation of Liver Regeneration. For a long time his research interest has focused on the cloning and identification of a liver-derived growth factor, namely hepatic stimulator substance (HSS) or augmenter of liver regeneration. His laboratory work includes HSS intracellular allocation and potential interaction with proteins from endoplasmic reticulum (ER) and mitochondria. Using genetic methods, his team has confirmed that loss of HSS expression will desensitize hepatocytes against intoxication probably due to impairment on ER Ca2+ homeostasis and mitochondrial dynamics. Meanwhile, his group found that HSS, as a potential cytokine, promotes HCC metastasis via activation of EMT pathway.

**Professor Wei An**  
Professor of Cell Biology,  
Capital Medical University
Session 5c  
BASIC AND TRANSLATIONAL

**SB05C03**  
*Clinical significance of over-expression of thymosin B4 in breast cancer-associated endothelial cells*

Dr Cai received his MD degree from Shanghai No.2 Medical University (presently Jiaotong University) in China. He completed his PhD in University of Wales College of Medicine (presently Cardiff University) in UK, investigating cancer metastasis and tumour angiogenesis. His research over the last decade has been advancing the field of regulatory role of vascular endothelial growth factor (VEGF) in pathological settings, such as tumour angiogenesis, proliferative diabetic retinopathy. His expertise is in the area of VEGF signalling. His research interest is expanding to dissect the molecular mechanisms associated with survival of the vasculatures within the tumour microenvironment.

**SB05C04**  
*Potential impact of anaesthetics on cancer cell biology*

Professor Ma is the Macintosh Professor and Head of Anaesthesia Research, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, and Chelsea and Westminster Hospital. He has more than 160 publications in the English peer reviewed journals and holds two international patents. His research is being supported by grants from MRC, Alzheimer’s Society-Bupa Foundation, BJA/RCoA, AAGBI, Westminster Medical School Research Trust, Action Medical Research and SPARKS, UK and European Society of Anaesthesiology, Brussels. He is a grant reviewer for Swiss National Science Foundation, The Ministry of Science, Education, Sports of the Republic of Croatia and NSFC, China, and Action Medical Research, MRC, and Wellcome Trust, UK. He has supervised more than sixteen PhD/MD students.

**SB05C05**  
*The association of ALK expression to ALK gene alterations in neuroblastoma*

Professor Gong began her research career in the Molecular Pathology Department at Capital Medical University after a PhD in pathology at Peking University Health Science Center and University of Cambridge. Combining with her histopathological background, she has a special interest in ALK-related tumours including neuroblastoma (NB) and anaplastic large cell lymphomas (ALCL). Her research interests include investigating the molecular basis of the tumours’ heterogeneity in both histology and clinic, and identifying the clinical implication of the genetic alterations of NB and ALCL.
Session 5c
BASIC AND TRANSLATIONAL

SB05C06
Designing drugs to tackle unmet medical need in breast cancer

Dr. Westwell is currently Reader in Medicinal Chemistry at the School of Pharmacy and Pharmaceutical Sciences at Cardiff University, having worked in Cardiff since 2006. He received his BSc (Hons) in Chemistry and PhD in organic chemistry at the University of Leeds. Following a postdoctoral fellowship at Loughborough University, he joined a Cancer Research UK programme at the University of Nottingham, initially as senior research fellow, later as Lecturer. Following his move to Cardiff he has established a number of collaborative research projects focusing on breast cancer drug discovery, new synthetic chemistry methods, and cancer imaging by Positron Emission Tomography (PET). He has published more than 100 journal articles and reviews. Technology transfer activities have included a number of patent filings, and he was lead chemist in Nottingham on the development of a new molecule from discovery at the bench to early clinical evaluation. Recently he has been one of the co-founders of Tiziana Life Sciences, an AIM-listed company focused on anti-metastatic cancer drug development. Other recent research related activities have included serving as honorary treasurer of the British Association for Cancer Research (2007-2012). He currently serves on the editorial board of the international journal, Future Medicinal Chemistry.

SB05C07
The genome-wide binding profile of notch family proteins in pancreatic cancer cells

Professor Zhang is currently a Professor in Biochemistry and Molecular Biology at Capital Medical University (CMU). After a PhD in Medical Sciences at Hiroshima University, Japan, Professor Zhang moved to the University of Minnesota and University of Maryland, USA, for postdoctoral training. In early 2005, he started working at CMU. His research focuses on the role of Notch signal transduction pathway in pancreatic cancer and findings include the cross-talk between EGFR and Notch pathways. His laboratory is investigating the role of different Notch proteins using CHIP-seq and proteomics techniques.
Session 5c
BASIC AND TRANSLATIONAL

SBO5C08
Unregulated micro RNA-21 levels in exosomes from cerebrospinal fluid of glioma patients associated with poor prognosis of invasive recurrence

Professor Wenbin Li is the Director of Glioma Programme, and Director of the Department of Medical Education, Beijing Shijitan Hospital, Capital Medical University. He is also Associate Professor of Neurosurgery, Peking University and Chief Doctor of Neuro-oncology, Capital Medical University. Dr Li is a Director of the Chinese Anti-Cancer Association and a board member on the Committee of Applied Pharmacology, Chinese Pharmaceutical Association. He is Director of the Beijing Medical Education Associate and a board member of Cancer Biology and Medical and of Current Signal Transduction Therapy. His research interests include immunotherapy and combined chemotherapy-radiotherapy for GBM and other types of brain tumour. He also conducts research to determine the relationships between MRI and various genomics alterations in GBM patients and miRs which could predict response to temozolomide in patients with GBM.

Professor Zhang is a Professor and doctor tutor in Peking University Cancer Hospital. He is Chief Surgeon in the Department of Thoracic Surgery in Beijing Cancer Hospital. He graduated from Capital Medical University in 1977. From Sept 2001 to Dec 2005, he pursued a doctorate in medicine in Cardiff University School of Medicine, UK. He obtained his doctor degree of medicine in 2006 and was a Visiting Scholar in the Surgery Department of the University of Wales College of Medicine. He was nominated for the British Council Outstanding Overseas Student Award in 2012. He was awarded as a distinguished Honorary Professor of Cardiff University in 2013. Memberships include the Standing Committee of Thoracic Surgery Association of China and Vice-Chairman of Thoracic Surgery Society of Beijing. As a National Science and Technology Award Evaluation Expert, he is China’s well-known expert in thoracic surgery and has published more than 80 papers.

Professor Zhang is an Associate Professor, Professor, President Assistant and Director of the Research Administration Department in Peking University Cancer Hospital and Institute. She has a broad education background in gynaecology and research administration. She was awarded her Master Degree of Medicine from Peking University Health Science Centre in 1988 and Master Degree of Science Management in 2003. She is well trained in scientific research administration; during 2006 she was a visiting scholar for one year in Dana Farber Cancer Institute of Harvard University. She has worked as an Obstetric and Gynaecological doctor for more than ten years, and as Director in the Department of Scientific Research Management in Peking University Cancer Hospital for more than seventeen years.
Our history in pictures
Developing relationships

May 2007: Beijing - Cardiff University signed an agreement of collaboration with Peking University. Cardiff delegation was led by Dr David Grant, Cardiff’s Vice-Chancellor. The Peking delegation was led by Peking’s Executive Vice-President, Professor Yang Ke. Professor Zhihong Xu, Peking’s President also attended.

July 2007: Cardiff University - Cardiff University signed an agreement of collaboration with Capital Medical University (CMU). In the same year, Cardiff University launched the China Medical Scholarship. The scholarship is funded by generous gifts from Mr Albert Hung and Henry Fong of Hong Kong.

October 2010: Great Hall of the People, Beijing - Cardiff University and Capital Medical University signed an agreement on scholar exchange.
Developing relationships 2011 – 2013

October 2011: Chongqing - Cardiff University signed an agreement with Chongqing Cancer Hospital on scholar exchange. The signing ceremony was part of the Welsh Government office visit.

February 2012: Cardiff University - Cardiff University’s Vice-Chancellor, Dr David Grant and Peking Cancer Hospitals President, Professor Jiafu Ji signed an agreement for collaboration.

October 2013: Jilin Hall, Great Hall of the People, Beijing - Capital Medical University conferred its title of ‘International Advisor’ to Professor Colin Riordan and the two institutions signed an MoU of cooperation in education between Cardiff University and CMU.
Developing relationships  2013 – 2015

October 2013: Beijing - ‘Cardiff University-Yiling Medical Institute Joint Medical Centre’ signed an agreement of collaboration in research. The agreement was signed by Professor Colin Riordan, Cardiff’s Vice-Chancellor and Professor Yiling Wu, Yiling’s Chairman.

October 2013: Beijing - Cardiff and Vale University Health Board and Beijing Health Bureau signed an overarching MoU for collaboration in medicine and medical training. The agreement was signed by the Chief Executive of the University Health Board, Professor Adam Cairns and Beijing Health Bureau Director General. The event was attended by CMU and Cardiff University.

April 2015: CCMRC, Cardiff University - Cardiff University and Beijing Municipal Government signed an MoU for education and exchange. Delegates included representation from Capital Medical University, Beijing University of Technology and Beijing University of Art and Design.
May 2012: Peking University, Peking Cancer Hospital and Institute, Beijing - The ‘Cardiff University-Peking University Joint Cancer Institute’ was launched (delegations led by Dr Grant and Professor Ji).
Building joint research structures

May 2012: CMU, Beijing - Cardiff’s Vice-Chancellor, Dr David Grant, and CMU’s President, Professor Zhaofeng Lu signed an agreement creating the ‘Cardiff University – Capital Medical University Joint Centre for Biomedical Research’. Cardiff’s Dean of Medicine, Professor B. Paul Morgan was awarded Honorary Professor by CMU.

October 2012: National Convention Centre, Beijing - Cardiff’s University’s major delegation attended Peking Health’s 100th Anniversary celebration, led by Cardiff University’s Vice-Chancellor, Professor Colin Riordan, and Professors Paul Morgan, Wen G. Jiang and John Robertson.

October 2012: Peking University, Beijing - Cardiff University’s President and Vice-Chancellor, Professor Colin Riordan visited the ‘Cardiff-Peking Joint Institute’ as part of his first international visit.
Building joint research structures

October 2012: CMU, Beijing - Cardiff’s President and Vice-Chancellor, Professor Colin Riordan visited CMU and the ‘Cardiff-CMU Joint Centre for Biomedical Research’ in Beijing as part of his first international visit.

March 2013: Glamorgan Building, Cardiff - The ‘Cardiff University-Peking University Joint Cancer Institute’ was formally launched. It was attended by the Minister of Education, MP, Mr Leyton Andrews and hosted by Cardiff University’s Professor Colin Riordan, President and Vice-Chancellor, Professor Dylan Jones, Pro Vice-Chancellor, Sir Martin Evans, Chancellor. The event was also attended by Cancer Research Wales’ President and Chairman, Professors John Moore, John Pritchard and Cardiff University’s Professors Malcolm Mason, Keith Harding and Robert Mansel. The plaque was unveiled by Mr Andrews, Professor Riordan and Professor Ji.
Building joint research structures

May 2013: Cardiff University - The ‘Cardiff University - Capital Medical University Joint Centre for Biomedical Research’ was officially launched.

October 2013: Beijing Capital Hotel, Beijing
‘Cardiff University-Yiling Medical Institute Joint Medical Centre’ was formally launched by Professor Colin Riordan, Cardiff’s President and Vice-Chancellor, and Professor Yiling Wu, Yiling’s Chairman.

June 2014: Beijing - The ‘Cardiff University - Capital Medical University Joint Centre for Biomedical Research’ was awarded the ‘Key Laboratory of Cancer Invasion and Metastasis’, and ‘Beijing International Base for Sino-UK Cancer Research’.
Building joint research structures

December 2014: CMU, Beijing. Cardiff delegation attended the first academic and scientific advisory meeting of the ‘Key Laboratory of Cancer Invasion and Metastasis’ at CMU.
Mutual visits and recognition

October 2010: Great Hall of the People, Beijing - Capital Medical University awarded Cardiff University’s Vice-Chancellor, Dr David Grant its prestigious ‘International Advisor’ title. The event was attended by the British Ambassador.

July 2011: Cardiff - Professor Zhaofeng Lu, CMU’s President, received the ‘Honorary Cardiff Fellow’ title in recognition of his contribution to medical education.

November 2011: Grosvenor House Hotel, Park Lane, London - At the annual Times Higher Education awards, Cardiff University won an award for “International Collaboration of the Year”. The award recognised Cardiff’s ground-breaking cancer research partnership work with Capital Medical University and Peking University.
Mutual visits and recognition

May 2012: Peking University Cancer Hospital and Institute - Peking conferred an ‘Honorary Professorship’ on Professor Sir Martin Evans and Professor Wen G. Jiang of Cardiff University.

May 2012: Beijing - Capital Medical University awarded ‘Honorary Professorship’ title to Sir Martin Evans, Cardiff University.

Nov 2012: Cardiff University - CMU’s first group of 10 postgraduate students arrived in Cardiff led by Professor Jinshu Yin (Vice-President of CMU’s Shijitan Hospital) and Professor Wenbin Li (Director of Education).
Mutual visits and recognition

February 2013: Glamorgan Building, Cardiff - Professor Jiafu Ji, President of Peking University Cancer Hospital and Institute, received distinguished ‘Honorary Professorship’ from Cardiff University, together with Professors Hao, Shen, Zhang, Su and Zhang.

May 2013: Cardiff University - Cardiff University awarded Professor Xiaomin Wang, CMU’s Vice-President, Cardiff’s distinguished ‘Honorary Professorship’.

October 2013: Health Science Centre, Beijing - Peking University awarded Cardiff’s President and Vice-Chancellor, Professor Colin Riordan it’s ‘Honorary Professorship’.
Mutual visits and recognition

June 2014: Olympic Village, Beijing - Cardiff University’s Professors’ Hywel Thomas and Malcolm Mason were awarded the Peking University Cancer Institute ‘Honorary Professorship’.

December 2014: Beijing - Professor Wen G. Jiang, on behalf of Cardiff University and Cardiff’s President and Vice-Chancellor, Professor Colin Riordan, attended the formal opening of the Peking University International Hospital and presented at the Peking University International Health Forum.
Mutual visits and recognition

December 2014: Cardiff and Beijing

Three Cardiff University Professors were awarded the title of ‘Key Advisor’ for Capital Medical University’s ‘Key Laboratory of Cancer Invasion and Metastasis.’ On behalf of Professor Xiaomin Wang, Vice-President of Capital Medical University, ‘Key Advisor’ Wen G. Jiang awarded the certificates to Sir Martin Evans and Professor Malcom Mason, Cardiff University. Professor Wang presented the certificate to Professor Shujun Cheng of the Chinese Academy of Science, who was also appointed.

January 2015: China

Cardiff delegation visited Capital Medical University, Chinese Academy of Science, Peking University, Xiamen University, South China University of Technology and Beijing Municipal Government to explore further collaboration opportunities in the field of medicine and healthcare.
Scholarship, students and scholars

February 2009: Cardiff University - The first group of China Medical Scholars, funded by Cardiff’s China Medical Scholarship arrived at Cardiff’s Medical School.

October 2010: Great Hall of the People, Beijing - Students and scholars who successfully completed their study and research at Cardiff University received their certificates. The presentations were attended by Cardiff’s Vice-Chancellor, Dr David Grant, CMU’s Vice-President, Professor Xiaomin Wang and the funder, Mr Albert Hung and Mrs Jessica Hung.
Scholarship, students and scholars

May 2012: Great Hall of the People, Beijing - Cardiff awarded certificates to the Chinese scholars who successfully completed their training at Cardiff University. The presentations were attended by Madam Meiying Zhang, Chinese Deputy Congress Leader, the British Embassy, Cardiff University, CMU and Peking University. The Cardiff delegation was led by Dr David Grant, Cardiff’s Vice-Chancellor. The Capital Medical University delegation was led by Vice-President, Zhongjun Guan. The Peking University delegation was led by Professor Jiafu Ji, President of Peking Cancer Hospital and Institute.
Scholarship, students and scholars 2012 – 2013

September 2012: National Conventional Centre, Beijing - Cardiff delegation participated in the China Clinical Oncology Congress and presented their research. Dr Sioned Owen received the presentation prize for ‘Young Scientist’.

June 2013: China - Cardiff University PhD students travelled to China for an exchange visit to Capital Medical University and Peking University, funded by MARG and Capital Medical University.

October 2013: Beijing - Cardiff University awarded certificates to the medical scholars who successfully completed their training in Cardiff.
April 2014: Xuanwu Hospital, Beijing - Cardiff delegation led by Cardiff University’s President and Vice-Chancellor Professor Riordan, visited Xuanwu Hospital of CMU with the Cardiff medical students.

June 2014: Beijing - Cardiff formally launched the ‘Yiling China Medical Scholarship’. Professor Thomas and Professor Yiling Wu awarded certificates to the incoming medical scholars.
Scholarship, students and scholars

September 2014: Capital Medical University, Beijing - Cardiff University’s PhD students, based at CCMRC, travelled to China as part of the exchange programme.

November 2014: Cardiff University - Capital Medical University students joined Cardiff University for an exchange placement. The students represented the first exchange between the two Universities since the launch of the ‘Joint Research Centre’ in 2013 and the signing of a “Memorandum of Understanding” in October 2014.
Scholarship, students and scholars

2014 – 2015

2014 and 2015: Beijing - Cardiff’s scholars and students in Capital Medical University and Peking University.
Scholarship, students and scholars

2014 – 2015

2014 and 2015: Cardiff - Students and scholars from China at Cardiff University.
Joint conferences

September 2012: Beijing - Cardiff delegation attended the first joint conference at Peking University Cancer Hospital.

June 2014: CMU, Beijing - CUKC 2014 was held at the CMU campus. The conference was attended by Cardiff University’s Professor Hywel Thomas, CMU’s Professor Zhaofeng Lu, Yilings Academicians’ Shujun Cheng and Yiling Wu, Beijing Municipal Commission of Education, Science, Technology and Health, together with 15 Cardiff University delegates and over 200 Beijing delegates.

June 2014: Beijing International Convention Centre - Peking University and Cardiff University Cancer Research Symposium was held as part of the CUKC conference. The UK delegation also participated in the 9th National Gastric Cancer Academic Conference and the 2nd Sunlight Great Wall Cancer Academic conference which was hosted by the Chinese Anti-Cancer Association/ Gastric Cancer Association and held by Peking University Cancer Hospital.
December 2014: CMU, Beijing - Cardiff delegation attended the first academic and scientific advisory meeting of the ‘Key Laboratory of Cancer Invasion and Metastasis’ at CMU.
The ‘Cardiff China Medical Alumni Association’ 2012 – 2014

September 2012: Olympic Village, Beijing - The ‘Cardiff China Medical Alumni Association’ was launched. Attending the ceremony were delegates from Cardiff University, Wales NHS, Peking University and CMU.

June 2014: Great Wall, Beijing - CCMRC members walked the Great Wall of China and raised money in support of Cancer Research Wales.

June 2014: Beijing - ‘Cardiff China Medical Alumni Association’ annual meeting 2014 was held. ‘Honorary advisors’ for the Alumni from China and UK were appointed.
Participating organisations
Participating organisations

Universities:
- Capital Medical University
- Cardiff University
- Guangdong Academy of Traditional Chinese Medicine
- Imperial College London
- Kings College London
- Peking University
- Qingdao University
- Sun-Yat Sen University
- Swansea University
- University College London (UCL)
- University of Bedfordshire
- University of Bristol
- University of Liverpool
- University of Oxford
- University of Salford
- University of Wolverhampton

Hospitals:
- Aintree University Hospital
- Airforce General Hospital
- Beijing Anzhen Hospital
- Beijing Cancer Hospital
- Beijing Chao-Yang Hospital
- Beijing Chest Hospital
- Beijing Friendship Hospital
- Beijing Shijitan Hospital
- Beijing Xuan Wu Hospital
- British Royal Infirmary
- Chelsea and Westminster Hospital
- Chongqing Cancer Hospital
- Churchill Hospital, Oxford
- Guangdong Province Hospital of Traditional Chinese Medicine
- Peking First Hospital (Beida Hospital)
- Shi Ji Tan Hospital
- Sun Yat-Sen Memorial Hospital
- Swansea Singleton Hospital
- Tiantan Hospital
- University Hospital Lewisham, London
- University Hospital Llandough
- University Hospital of Wales
- Velindre Hospital
- Wrexham Maelor Hospital
- Xuanwu Hospital
- Yu Huang Ding Hospital
- Yantai Yuhuangding Hospital

Organisations:
- British Association of Surgical Oncology (BASO)
- Compton Group
- Life Sciences Research Network, Ser Cymru
- National Health Service (NHS)
- Royal Society of Medicine
- University Health Board (UHB, Cardiff and The Vale)
- Velindre Cancer Centre
- Welsh Government

Sponsors

Main sponsor
Cardiff and Vale University Health Board

Silver sponsor
Cancer Research Wales

Bronze sponsor
Geneflow
Life Sciences Research Network Wales
Life Technologies
Merck Millipore
Olympus
Primer Design
Sigma-Aldrich
Wolf Laboratories